

STERIS CORP
Form 10-Q
February 09, 2010
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2009

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 1-14643

STERIS Corporation

(Exact name of registrant as specified in its charter)

Edgar Filing: STERIS CORP - Form 10-Q

Ohio (State or other jurisdiction of incorporation or organization)	34-1482024 (IRS Employer Identification No.)
5960 Heisley Road, Mentor, Ohio (Address of principal executive offices)	44060-1834 (Zip code)
440-354-2600 (Registrant's telephone number, including area code)	

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer
Non-Accelerated Filer

Accelerated Filer
Smaller Reporting Company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of common shares outstanding as of January 29, 2010: 59,126,129

Table of Contents

STERIS Corporation and Subsidiaries

Form 10-Q

Index

	Page
Part I Financial Information	
Item 1. <u>Financial Statements</u>	3
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	27
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	44
Item 4. <u>Controls and Procedures</u>	44
Part II Other Information	
Item 1. <u>Legal Proceedings</u>	45
Item 1A. <u>Risk Factors</u>	47
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	48
Item 5. <u>Other Information</u>	48
Item 6. <u>Exhibits</u>	49
<u>Signature</u>	50

Table of Contents**PART I FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****STERIS CORPORATION AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

(in thousands)

	December 31, 2009 (Unaudited)	March 31, 2009
Assets		
Current assets:		
Cash and cash equivalents	\$ 265,419	\$ 154,180
Accounts receivable (net of allowances of \$9,059 and \$10,728, respectively)	207,087	238,438
Inventories, net	128,413	130,218
Current portion of deferred income taxes, net	5,472	7,195
Prepaid expenses and other current assets	20,338	23,099
Total current assets	626,729	553,130
Property, plant, and equipment, net	347,346	350,996
Goodwill and intangibles, net	311,859	305,189
Other assets	9,755	7,624
Total assets	\$ 1,295,689	\$ 1,216,939
Liabilities and shareholders equity		
Current liabilities:		
Accounts payable	\$ 55,703	\$ 68,573
Accrued payroll and other related liabilities	50,000	59,702
Accrued expenses and other	70,038	73,751
Total current liabilities	175,741	202,026
Long-term debt	310,000	210,000
Deferred income taxes, net	18,017	18,109
Other liabilities	58,771	68,639
Total liabilities	562,529	498,774
Commitments and contingencies (see note 10)		
Serial preferred shares, without par value; 3,000 shares authorized; no shares issued or outstanding		
Common shares, without par value; 300,000 shares authorized; 70,040 shares issued; 59,127 and 58,452 shares outstanding, respectively	236,011	232,282
Common shares held in treasury, 10,914 and 11,588 shares, respectively	(297,605)	(313,105)
Retained earnings	775,482	814,359
Accumulated other comprehensive income (loss)	18,492	(15,800)
Total shareholders equity	732,380	717,736
Noncontrolling interest	780	429
Total equity	733,160	718,165

Total liabilities and equity

\$ 1,295,689 \$ 1,216,939

See notes to consolidated financial statements.

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF INCOME**

(in thousands, except per share amounts)

(Unaudited)

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2009	2008	2009	2008
Revenues:				
Product	\$ 214,072	\$ 203,308	\$ 586,707	\$ 602,746
Service	113,760	116,159	338,897	351,413
Total revenues	327,832	319,467	925,604	954,159
Cost of revenues:				
Product	122,324	127,111	332,559	360,901
Service	66,025	68,289	196,071	206,327
Total cost of revenues	188,349	195,400	528,630	567,228
Gross profit	139,483	124,067	396,974	386,931
Operating expenses:				
Selling, general, and administrative	71,776	67,272	220,897	231,910
Research and development	8,265	8,122	24,035	24,469
Restructuring expenses	14	2,855	(313)	2,726
Total operating expenses	80,055	78,249	244,619	259,105
Income from operations	59,428	45,818	152,355	127,826
Non-operating expenses, net:				
Interest expense	3,291	3,214	9,504	7,499
Interest and miscellaneous income	(535)	(366)	(1,031)	(1,288)
Total non-operating expenses, net	2,756	2,848	8,473	6,211
Income before income tax expense	56,672	42,970	143,882	121,615
Income tax expense	15,666	14,395	45,250	38,746
Net income	\$ 41,006	\$ 28,575	\$ 98,632	\$ 82,869
Net income per common share:				
Basic	\$ 0.70	\$ 0.49	\$ 1.68	\$ 1.41
Diluted	\$ 0.69	\$ 0.48	\$ 1.66	\$ 1.39
Cash dividends declared per common share outstanding	\$ 2.11	\$ 0.08	\$ 2.33	\$ 0.22

See notes to consolidated financial statements.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Nine Months Ended December 31,	
	2009	2008
Operating activities:		
Net income	\$ 98,632	\$ 82,869
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation, depletion, and amortization	42,027	43,876
Deferred income taxes	1,171	10,868
Share based compensation	5,613	5,653
Loss (gain) on the disposal of property, plant, equipment and intangibles	1,477	(1,445)
Other items	4,016	(8,346)
Changes in operating assets and liabilities		
Accounts receivable, net	38,064	25,735
Inventories, net	9,275	(12,759)
Prepaid expenses and other current assets	3,356	10,663
Accounts payable	(14,837)	(13,333)
Accruals and other, net	(30,126)	(35,457)
Net cash provided by operating activities	158,668	108,324
Investing activities:		
Purchases of property, plant, equipment, and intangibles	(29,839)	(29,704)
Proceeds from the sale of property, plant, equipment, and intangibles	574	10,981
Equity investment in joint venture	(1,500)	(4,150)
Net cash used in investing activities	(30,765)	(22,873)
Financing activities:		
Proceeds from the issuance of long-term obligations		150,000
Payments on long-term obligations		(40,500)
Proceeds (payments) under credit facilities, net	100,000	(79,180)
Deferred financing fees and debt issuance costs		(476)
Repurchases of common shares	(289)	(80,466)
Cash dividends paid to common shareholders	(137,509)	(12,981)
Stock option and other equity transactions, net	12,339	33,254
Tax benefit from stock options exercised	1,927	8,766
Net cash used in financing activities	(23,532)	(21,583)
Effect of exchange rate changes on cash and cash equivalents	6,868	(9,686)
Increase in cash and cash equivalents	111,239	54,182
Cash and cash equivalents at beginning of period	154,180	51,868
Cash and cash equivalents at end of period	\$ 265,419	\$ 106,050

See notes to consolidated financial statements.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

STERIS Corporation, an Ohio corporation, develops, manufactures and markets infection prevention, contamination control, microbial reduction, and surgical and critical care support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental Customers throughout the world. As used in this Quarterly Report, STERIS Corporation and its subsidiaries together are called STERIS, the Company, we, us, or our, unless otherwise noted.

We operate in three reportable business segments: Healthcare, Life Sciences, and STERIS Isomedix Services (Isomedix). We describe our business segments in note 11 to our consolidated financial statements titled, Business Segment Information. Our fiscal year ends on March 31. References in this Quarterly Report to a particular year or year-end mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:

Interim Financial Statements

We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.

These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the Securities and Exchange Commission (SEC) on May 29, 2009. The Consolidated Balance Sheet at March 31, 2009 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

Principles of Consolidation

We use the consolidation method to report our investment in our subsidiaries. Consolidation means that we combine the accounts of our wholly-owned subsidiaries with our accounts. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts.

Use of Estimates

We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2009 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2010.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

Fair Value of Financial Instruments

The recorded value of financial instruments is approximately equal to the fair value. We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. We determined that the recorded value of our long-term debt is approximately equal to the fair value at December 31, 2009 and March 31, 2009. The financial instruments that we hold could potentially expose us to a concentration of credit risk. We invest our excess cash in highly rated money market funds and other high-quality short-term investments placed with major banks and financial institutions. We have established guidelines related to diversification and maturities to maintain safety and liquidity.

We provide additional information regarding the fair value of our financial instruments in note 17 titled, Fair Value Measurements.

Recently Adopted Accounting Pronouncements

In September 2006, the Financial Accounting Standards Board (FASB) issued a new standard to define fair value, establish a framework for measuring fair value in accordance with U.S. GAAP and expand disclosures about fair value measurements. In February 2008, the FASB deferred the effective date of the standard for all nonfinancial assets and liabilities to fiscal years beginning after November 15, 2008. We adopted the required provisions of the standard for financial assets and liabilities on April 1, 2008 and for nonfinancial assets and liabilities on April 1, 2009. The adoption did not have a material impact on our consolidated financial statements.

In December 2007, the FASB issued a new standard regarding the accounting for business combinations. The standard retains the purchase method of accounting for acquisitions, but requires a number of changes, including changes in the way assets and liabilities are recognized in purchase accounting. It also changes the recognition of assets acquired and liabilities assumed arising from contingencies, requires the capitalization of in-process research and development at fair value, and requires the expensing of acquisition-related costs as incurred. The changes will impact financial statements on the acquisition date and in subsequent periods, as well as prior to the acquisition date because of the accounting treatment for acquisition-related costs. The provisions will be applied prospectively to business combinations completed in fiscal years beginning after December 15, 2008.

In December 2007, the FASB issued a new standard regarding the accounting for noncontrolling interests in consolidated financial statements. The standard recharacterizes minority interests as noncontrolling interests and requires these interests to be classified as a separate component of equity in our consolidated financial statements. Purchases or sales of equity interests that do not result in a change in control will be accounted for as equity transactions. In addition, net income related to the noncontrolling interests will be included in our consolidated net income and, upon a loss of control, the interest sold, as well as any interest retained, will be recorded at fair value with any gain or loss recognized in earnings. The provisions of the standard will be applied prospectively, except for the presentation and disclosure requirements, which will apply retrospectively, and are effective for the first annual reporting period beginning after December 15, 2008. We adopted the standard as of April 1, 2009, applying the presentation and disclosure requirements retrospectively resulting in reclassification of noncontrolling interests from Other liabilities to Total equity. Income attributable to noncontrolling interests is included in Selling, general and administrative expenses in the Consolidated Statements of Income and is not material.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

In March 2008, the FASB issued a new standard regarding disclosures about derivative instruments and hedging activities. The standard requires disclosures regarding how and why an entity uses derivative instruments, how derivative instruments and related hedged items are accounted for, and how derivative instruments and related hedged items affect an entity's financial position, results of operations, and cash flows. The standard is effective for fiscal years beginning after November 15, 2008, with early adoption permitted. We adopted the standard on April 1, 2009 and it did not have a material impact on our consolidated financial statements.

In December 2008, the FASB issued a staff position regarding employers' disclosures about postretirement benefit plan assets. It requires us to disclose how investment allocation decisions are made, including the factors relevant to understanding investment policies and decisions, the major categories of plan assets, the inputs and valuation techniques used to measure the fair value of the plan assets, the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets for the period, and significant concentrations of risk within plan assets. The provisions are effective for fiscal years ending after December 15, 2009 and will increase the disclosures in the notes to our consolidated financial statements related to the assets of defined benefit pension plans.

In April 2008, the FASB issued a staff position which amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset. The provisions apply prospectively to intangible assets acquired after the effective date in fiscal years beginning after December 15, 2008. The adoption did not have a material impact on the consolidated financial statements.

In June 2008, the FASB issued a staff position which provides that unvested share-based payment awards that contain rights to receive non-forfeitable dividends (whether paid or unpaid) are participating securities, and should be included in the two-class method of computed earnings per share. The position is effective for fiscal years beginning after December 15, 2008, and interim periods within those years. The adoption did not have a material impact on our disclosure of earnings per share.

In April 2009, the FASB issued several staff positions related to the accounting and financial statement disclosures of financial instruments that are effective for interim periods ending after June 15, 2009. All are to be applied prospectively and require comparative disclosures only for periods ending after initial adoption. The positions 1) change existing accounting requirements for other than temporary impairment of debt securities, 2) provide guidance for valuation of assets and liabilities that have experienced a significant reduction in volume and activity in relation to normal market activity, and 3) prospectively extend the disclosure requirements regarding the fair value of financial instruments, to interim financial statements. The adoption of these positions did not have a material impact on the consolidated financial statements.

In May 2009, the FASB issued a new standard requiring the disclosure of the date through which an entity has evaluated subsequent events and the basis for that date. The provisions are effective for interim and annual periods ending after June 15, 2009. The adoption did not have a material impact on our consolidated financial statements.

In June 2009, the FASB issued a standard that establishes only two levels of U.S. GAAP, authoritative and nonauthoritative. The FASB Accounting Standards Codification (the Codification) is now the sole source of authoritative, nongovernmental U.S. GAAP, except for rules and interpretive releases of the SEC, which are sources of authoritative GAAP for SEC registrants. All other non-grandfathered, non-SEC accounting literature not included in the Codification will become nonauthoritative. This standard is effective for financial statements

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

for interim or annual reporting periods ending after September 15, 2009. As the Codification was not intended to change or alter existing GAAP, the adoption did not have any impact on our consolidated financial statements.

Significant Accounting Policies

A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2009.

2. Restructuring

The following summarizes our restructuring plans announced in prior fiscal years. We recognize restructuring expenses as incurred. In addition, we assess the property, plant and equipment associated with the related facilities for impairment. Additional information regarding our respective restructuring plans is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009.

Fiscal 2009 Restructuring Plan

During the third quarter of fiscal 2009, we adopted a restructuring plan primarily focused on our international operations (the Fiscal 2009 Restructuring Plan). As part of this plan, we took actions to improve operations at our Pieterlen, Switzerland manufacturing facility, rationalized certain products, recorded impairment charges for certain assets no longer used, and made targeted workforce reductions. We have closed two sales offices in Japan. These actions directly impacted approximately 100 employees worldwide. These restructuring actions are intended to enhance our profitability and improve efficiency primarily by reducing ongoing international operating costs.

Since the inception of the Fiscal 2009 Restructuring Plan, we have incurred pre-tax expenses totaling \$14,784 related to these actions, of which \$4,455 was recorded as restructuring expenses and \$10,329 was recorded in cost of revenues, with expenses of \$12,061 and \$2,723 related to the Healthcare and Life Sciences reporting segments, respectively. We do not expect to incur significant additional expenses related to the Fiscal 2009 Restructuring Plan. We are continuing to evaluate all of our operations for additional opportunities to improve performance, but we have not committed to any additional specific actions.

Fiscal 2008 Restructuring Plan

During the fourth quarter of fiscal 2008, we announced an expense reduction initiative which was primarily focused on our North American operations, and was intended to enhance our profitability and improve efficiency by reducing ongoing operating costs (the Fiscal 2008 Restructuring Plan). We did not incur any restructuring expenses related to the Fiscal 2008 Restructuring Plan in the three and nine month periods ended December 31, 2009.

Since the inception of the Fiscal 2008 Restructuring Plan, we have incurred pre-tax restructuring expenses totaling \$14,333 related to these actions, of which \$9,883 was recorded as restructuring expenses and \$4,450 was recorded in cost of revenues, with restructuring expenses and cost of revenues of \$11,856, \$1,296, \$429, and \$752 related to the Healthcare, Life Sciences, and Isomedix reporting segments, and Corporate and other, respectively. We do not expect to incur any significant additional restructuring expenses related to the Fiscal 2008 Restructuring Plan.

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)****European Restructuring Plan**

During the third quarter of fiscal 2007, we adopted a restructuring plan related to certain of our European operations (the European Restructuring Plan). During the first quarter of fiscal 2009, we settled the remaining obligations associated with this plan.

Fiscal 2006 Restructuring Plan

During fiscal 2006, we announced the transfer of the Erie, Pennsylvania manufacturing operations to Monterrey, Mexico and other restructuring actions (the Fiscal 2006 Restructuring Plan), which were intended to improve our cost structure. We settled all obligations associated with this plan in fiscal 2009.

The following tables summarize our total restructuring expenses for the third quarter and first nine months of fiscal 2010 and fiscal 2009:

	Fiscal 2009 Restructuring Plan (1)
Three Months Ended December 31, 2009	
Severance, payroll, and other related costs	\$ (23)
Product rationalization	(232)
Lease termination obligations and other	18
Asset impairment	9
Total restructuring charges	\$ (228)

(1) Includes \$(242) in charges recorded in cost of revenues on Consolidated Statements of Income.

	Fiscal 2009 Restructuring Plan	Fiscal 2008 Restructuring Plan	Total
Three Months Ended December 31, 2008			
Severance, payroll, and other related costs	\$ 3,362	\$ (107)	\$ 3,255
Asset impairment and accelerated depreciation	1,112	(83)	1,029
Product rationalization	9,100	(528)	8,572
Lease termination obligations		(17)	(17)
Other	113	(609)	(496)
Total restructuring charges	\$ 13,687	\$ (1,344)	\$ 12,343

Nine Months Ended December 31, 2009

	Fiscal 2009 Restructuring Plan (2)
Severance, payroll, and other related costs	\$ (36)
Product rationalization	(466)
Lease termination obligations and other	(290)
Asset impairment	(5)
Total restructuring charges	\$ (797)

(2) Includes \$(484) in charges recorded in cost of revenues on Consolidated Statements of Income.

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)**

Nine Months Ended December 31, 2008	Fiscal 2009 Restructuring Plan	Fiscal 2008 Restructuring Plan	European Restructuring Plan	Fiscal 2006 Restructuring Plan	Total
Severance, payroll, and other related costs	\$ 3,362	\$ (191)	\$	\$ (178)	\$ 2,993
Asset impairment and accelerated depreciation	1,112	(83)			1,029
Product rationalization	9,100	(523)			8,577
Lease termination obligations		20	99		119
Other	113	(609)			(496)
Total restructuring charges	\$ 13,687	\$ (1,386)	\$ 99	\$ (178)	\$ 12,222

Liabilities related to our restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within Accrued payroll and other related liabilities and Accrued expenses and other. The following table summarizes our liabilities related to these restructuring activities:

	Fiscal 2009 Restructuring Plan Fiscal 2010			
	March 31, 2009	Provision	Payments/ Impairments	December 31, 2009
Severance and termination benefits	\$ 1,920	\$ (36)	\$ (1,690)	\$ 194
Product rationalization	75	(466)	391	
Lease termination obligations and other	578	(290)	(245)	43
Asset impairment		(5)	5	
Total	\$ 2,573	\$ (797)	\$ (1,539)	\$ 237

	Fiscal 2008 Restructuring Plan Fiscal 2010			
	March 31, 2009	Provision	Payments/ Impairments	December 31, 2009
Severance and termination benefits	\$ 501	\$	\$ (392)	\$ 109
Asset impairments	409		(120)	289
Lease termination obligations and other	881		(392)	489
Total	\$ 1,791	\$	\$ (904)	\$ 887

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)****3. Comprehensive Income**

Comprehensive income includes net income as currently reported under U.S. GAAP and other comprehensive income. Other comprehensive income considers the effects of additional economic events that are not required to be recorded in determining net income, but rather are reported as a separate component of shareholders' equity. The following table illustrates the components of our comprehensive income:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2009	2008	2009	2008
Net income	\$ 41,006	\$ 28,575	\$ 98,632	\$ 82,869
Cumulative foreign currency translation adjustment	3,073	(31,600)	34,667	(55,970)
Reduction in the unrecognized postretirement benefit plan obligation, net of taxes		6,458		28,652
Amortization of pension and postretirement benefit plans costs, net of taxes	(246)	(494)	(651)	(739)
Unrealized gains (losses) on investments	7		276	(273)
Total comprehensive income	\$ 43,840	\$ 2,939	\$ 132,924	\$ 54,539

The reduction in the unrecognized postretirement benefit plan obligation, net of taxes recorded in the three and nine month periods ended December 31, 2008 is a result of amending and restating our United States postretirement welfare benefits plan during the third quarter of fiscal 2009. Additional information regarding the amendment and restatement of our United States postretirement welfare benefits plan is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009.

4. Property, Plant and Equipment

Information related to the major categories of our property, plant and equipment is as follows:

	December 31, 2009	March 31, 2009
Land and land improvements (1)	\$ 26,338	\$ 25,795
Buildings and leasehold improvements	192,960	188,136
Machinery and equipment	276,466	271,122
Information systems	101,264	92,966
Radioisotope	170,934	161,415
Construction in progress (1)	24,317	17,667
Total property, plant, and equipment	792,279	757,101
Less: accumulated depreciation and depletion	(444,933)	(406,105)
Property, plant, and equipment, net	\$ 347,346	\$ 350,996

Edgar Filing: STERIS CORP - Form 10-Q

- (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)****5. Inventories, Net**

Inventories, net are stated at the lower of cost or market. We use the last-in, first-out (LIFO) and first-in, first-out cost methods. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management's estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:

	December 31, 2009	March 31, 2009
Raw materials	\$ 36,212	\$ 37,270
Work in process	24,771	24,314
Finished goods	67,430	68,634
Inventories, net	\$ 128,413	\$ 130,218

6. Debt

Indebtedness was as follows:

	December 31, 2009	March 31, 2009
Private Placement	\$ 210,000	\$ 210,000
Credit facility	100,000	
Long-term debt	\$ 310,000	\$ 210,000

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)****7. Additional Consolidated Balance Sheets Information**

Additional information related to our Consolidated Balance Sheets is as follows:

	December 31, 2009	March 31, 2009
Accrued payroll and other related liabilities:		
Compensation and related items	\$ 11,863	\$ 17,395
Accrued vacation/paid time off	6,771	5,916
Accrued bonuses	18,070	22,973
Accrued employee commissions	8,964	9,100
Other postretirement benefit plan obligation-current portion	3,777	3,777
Other employee benefit plan obligations-current portion	555	541
Total accrued payroll and other related liabilities	\$ 50,000	\$ 59,702
Accrued expenses and other:		
Deferred revenues	\$ 25,770	\$ 25,491
Self-insured risk retention-current portion	6,590	6,083
Accrued dealer commissions	6,688	6,389
Accrued warranty	6,534	7,573
Other	24,456	28,215
Total accrued expenses and other	\$ 70,038	\$ 73,751
Other liabilities:		
Self-insured risk retention-long-term portion	\$ 11,041	\$ 11,041
Other postretirement benefit plan obligation-long-term portion	24,412	26,105
Defined benefit pension plan obligations	10,077	18,356
Other employee benefit plan obligations-long-term portion	1,979	1,240
Accrued long-term income taxes	11,262	11,897
Total other liabilities	\$ 58,771	\$ 68,639

8. Income Tax Expense

Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates from continuing operations for the three month periods ended December 31, 2009 and 2008 were 27.6% and 33.5%, respectively. For the nine month periods ended December 31, 2009 and 2008, the effective income tax rates from continuing operations were 31.4% and 31.9%, respectively. The lower effective income tax rate for the three month period ended December 31, 2009 resulted principally from discrete item adjustments and tax planning initiatives.

Edgar Filing: STERIS CORP - Form 10-Q

Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carryforwards, and available tax planning alternatives.

As of March 31, 2009, we had \$10,926 in unrecognized tax benefits, of which \$2,223 would favorably impact the effective tax rate if recognized. As of December 31, 2009, we had \$10,029 in unrecognized tax

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)**

benefits, of which \$1,516 would impact the effective tax rate if recognized. The decrease in unrecognized tax benefits for the three and the nine month periods ended December 31, 2009 is primarily due to the settlement of certain tax years under examination in the United States. We currently do not anticipate any significant increase or decrease in unrecognized tax benefits within 12 months of December 31, 2009. As of December 31, 2009, we have recognized a liability for interest of \$1,092 and penalties of \$141.

We file income tax returns in the United States and in various state, local, and foreign jurisdictions. For United States federal income tax purposes, we are closed through examination for years through fiscal 2007. With limited exceptions, we are no longer subject to state and local income tax examinations within the United States, or income tax examinations outside the United States, for years before fiscal 2005.

9. Benefit Plans

We provide defined benefit pension plans for certain current and retired manufacturing and plant administrative personnel throughout the world as determined by collective bargaining agreements or employee benefit standards set at the time of acquisition of certain businesses. In addition to providing pension benefits to certain employees, we sponsor an unfunded postretirement welfare benefits plan for two groups of United States employees including the same employees who receive pension benefits under the United States defined benefit pension plans. Benefits under this plan include retiree life insurance and retiree medical coverage, including prescription drug coverage. Additional information regarding our defined benefit pension plans and other postretirement benefits plan is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009.

Components of the net periodic benefit cost of our defined benefit pension plans and other postretirement medical benefit plan were as follows:

	Defined Benefit Pension Plans				Other	
	United States Qualified		International		Postretirement Benefits Plan	
	2009	2008	2009	2008	2009	2008
Three Months Ended December 31,						
Service cost	\$ 59	\$ 53	\$ 137	\$ 113	\$	\$
Interest cost	761	691	81	135	487	506
Expected return on plan assets	(617)	(719)	(89)	(147)		
Recognized loss (gain)	290	159		(500)	157	364
Curtailment/settlement			(19)			
Amortization of transition obligation	(18)	(28)				
Prior service cost					(816)	(1,295)
Net periodic benefit cost	\$ 475	\$ 156	\$ 110	\$ (399)	\$ (172)	\$ (425)

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)**

Nine Months Ended December 31,	Defined Benefit Pension Plans				Other	
	United States Qualified		International		Postretirement Benefits Plan	
	2009	2008	2009	2008	2009	2008
Service cost	\$ 178	\$ 158	\$ 354	\$ 340	\$	\$
Interest cost	2,283	2,072	243	404	1,461	2,197
Expected return on plan assets	(1,851)	(2,156)	(276)	(442)		
Recognized loss (gain)	869	477		(500)	470	1,003
Curtailment/settlement			(38)			
Amortization of transition obligation	(53)	(83)				
Prior service cost					(2,447)	(2,590)
Net periodic benefit cost	\$ 1,426	\$ 468	\$ 283	\$ (198)	\$ (516)	\$ 610

We contribute amounts to the defined benefit pension plans at least sufficient to meet the minimum requirements as stated in applicable employee benefit laws and local tax laws. We record liabilities for the difference between the fair value of the plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated postretirement benefit obligation for other postretirement benefits plans) on our accompanying Consolidated Balance Sheets.

10. Contingencies

We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise from the ordinary course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), economic loss (e.g., breach of contract, other commercial claims), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.

We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse affect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations (including without limitation the FDA-related matters discussed below), or other claims or proceedings. For certain types of claims, we presently maintain product liability insurance coverage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.

We record accruals for such contingencies to the extent that we conclude that their occurrence is both probable and estimable. We consider many factors in making these assessments, including the professional judgment of experienced members of management and our legal counsel. We have estimated the likelihood of unfavorable outcomes and the amounts of such potential losses. In management's opinion, the ultimate outcome of these proceedings and claims is not expected to have a material adverse effect on our consolidated financial

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

position, results of operations, or cash flows. However, the ultimate outcome of claims, litigation, and other proceedings is unpredictable and actual results could be materially different from our estimates. We record expected recoveries under applicable insurance contracts when we are assured of recovery.

The United States Food and Drug Administration (FDA) and the United States Department of Justice had been conducting an investigation to our knowledge since 2003 involving our STERIS SYSTEM 1® sterile processing system. We had received requests for documents, including the subpoena received in January 2005, and were aware of interviews of current and former employees in connection with the investigation. We responded to these requests and cooperated with the government agencies regarding this matter. We were advised by the United States Attorney's Office for the Northern District of Ohio in May 2009 that it was declining to pursue the investigation.

On May 16, 2008, we received a warning letter (the warning letter) from the FDA regarding our STERIS SYSTEM 1 sterile processor and the STERIS 20 sterilant used with the processor (sometimes referred to collectively in the FDA letter and in this note 10 as the device). We believe this warning letter arose from the previously disclosed investigation. In summary, the warning letter included the FDA's assertion that significant changes or modifications have been made in the design, components, method of manufacture, or intended use of the device beyond the FDA's 1988 clearance, such that the FDA believes a new premarket notification submission (known within FDA regulations as a 510(k) submission) should have been made. The warning letter referenced a number of changes to the device that, according to the FDA, require a new premarket notification submission, and asserted that our failure to make such a submission resulted in violations of applicable law. The warning letter also requested documentation and explanation regarding various corrective actions related to the device prior to 2003, and whether those actions should be considered corrections or removals requiring notice under applicable FDA regulations. On July 30, 2008 (with an Addendum on October 9, 2008), we provided a detailed response contending that the assertions in the warning letter were not correct.

On November 4, 2008, we received a letter from the FDA (dated November 3, 2008) in which the FDA stated without elaboration that, after reviewing our response, it disagreed with our position and that a new premarket notification submission is required. The agency did not address the removal and correction reporting issues and invited a meeting with STERIS to discuss the warning letter, based on our earlier request. After discussions with the FDA regarding the November 3rd letter, we received an additional letter on November 6, 2008 from the FDA. The November 6th letter stated that the intent of the November 3rd letter was to inform us of the FDA's preliminary disagreement with our response to the warning letter and, before finalizing a position, the FDA reiterated that it wanted to meet with us to discuss the Company's response, issues related to the warning letter and next steps to resolve any differences between the Company and the FDA.

We thereafter met with the FDA and, on January 20, 2009, we announced that we submitted to the FDA a new liquid chemical sterilant system for 510(k) clearance. The new submission followed discussions with the FDA regarding the prior 510(k) submission issues raised in the warning letter related to our existing device. We believe the new liquid chemical sterilant system submitted to the FDA addresses the changes referenced by the FDA in the warning letter and includes additional technology updates. However, we have no assurance the FDA will clear the new system for sale or that the system will receive market acceptance. Also in the January 20, 2009 announcement, based on discussion with the FDA, we communicated to Customers that we would continue supporting the existing STERIS SYSTEM 1 installed base for at least a two year period by providing accessories, sterilant, service and parts, and replacement processor units.

On December 3, 2009, the FDA provided a notice (notice) to healthcare facility administrators and infection control practitioners describing FDA's concerns about the STERIS SYSTEM 1 Processor, components and accessories, and FDA recommendations. In that notice, FDA stated its belief that the STERIS SYSTEM 1

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

device had been significantly modified, that FDA had not cleared or approved the modified device, and that FDA has not determined whether the STERIS SYSTEM 1 is safe or effective for its labeled claims. The notice further stated that use of a device that does not properly sterilize or disinfect a medical or surgical device poses risks to patients and users, including the transmission of pathogens, exposure to hazardous chemicals and affect on the quality and functionality of reprocessed instruments. The notice stated that FDA was aware of reports of malfunctions of the STERIS SYSTEM 1 that had the potential to cause or contribute to serious injuries to patients, such as infections, or injuries to healthcare staff, such as burns. Included in FDA's December 3, 2009 notice was a recommendation from FDA that if users had acceptable alternatives to meet sterilization and disinfection needs, users should transition to that alternative as soon as possible. On December 10, 2009, the FDA stated its belief that Customers should be able to transition from STERIS SYSTEM 1® within three to six months.

Since the December 3, 2009 notice, the FDA has engaged in discussions with healthcare providers, professional organizations, STERIS and others regarding this notice, its impact on users, the process of transition, acceptable alternatives, considerations for healthcare providers concerning continued use of and transition from STERIS SYSTEM 1, and the timing of such transition. On February 2, 2010, the FDA updated its December 10, 2009 information by extending to 18 months the total recommended time period for transitioning from SYSTEM 1 to acceptable alternative devices. We have continued to provide accessories, sterilant, service, and parts for STERIS SYSTEM 1 pursuant to FDA's enforcement discretion. At this time, we are also continuing discussions with FDA regarding possible resolution of this matter. On February 5, 2010, a complaint was filed by a Customer who claims to have purchased two STERIS SYSTEM 1 devices from STERIS. *Physicians of Winter Haven LLC d/b/a Day Surgery Center v. Steris Corp.*, Case No. 1:1-cv-00264-CAB (N.D. Ohio). The complaint alleges statutory violations, breaches of various warranties, negligence, failure to warn, and unjust enrichment. Plaintiff seeks class certification, damages, and other legal and equitable relief including, without limitation, attorneys' fees and an order requiring STERIS to replace, recall or adequately repair the product and/or to take appropriate regulatory action. We are evaluating this matter and expect to defend against these allegations.

There is no assurance that discussions with FDA will continue, that a resolution will be reached, that enforcement discretion will continue, that other lawsuits will not be brought, that the FDA or third party claimants will not pursue judicial, administrative or other legal or enforcement action or seek other remedies, including a recall or an immediate demand that STERIS stop further sales of the SYSTEM 1 device and any related accessories, services and sterilant, product replacement, or damages, or that FDA or third party claimants will not take other action as described in this note and/or in the Item entitled "Risk Factors" contained in this Form 10-Q or in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the Securities and Exchange Commission (SEC) on May 29, 2009.

We continue to believe that the changes described in the warning letter and the notice from the FDA do not significantly affect the safety or effectiveness of the device and, therefore, did not and do not require a new premarket notification submission, and further, that the corrective actions also described in the warning letter were compliant with FDA regulations. However, if the FDA's assertions are ultimately determined to be correct, the device would be considered adulterated and misbranded under United States law, in which case, we would be required to make a new premarket notification submission. The FDA also could take enforcement action immediately without providing the opportunity to make a new 510(k) submission. If we did not make that 510(k) submission, if the FDA rejected that 510(k) submission, if the FDA took immediate enforcement action or if governmental agencies and/or third parties otherwise considered the device to be non-compliant, civil, administrative, or criminal proceedings could be initiated. These or other proceedings involving our STERIS SYSTEM 1® sterile processing system and STERIS™ 20 sterilant, a significant product to us, could possibly result in judgments, settlements or administrative or judicial decrees requiring re-labeling or restriction on the

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

manufacturing, sale, or distribution of products, or could require us to take other actions, including recalls, to pay fines or civil damages, or to be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations. Most of the STERIS SYSTEM 1 sales are within the United States. It is unclear what impact the FDA's action, litigation, or other events described may have on sales of the device outside the United States. We intend to continue our discussions with the FDA to seek resolution of all issues described in the warning letter, the December 3rd notice and any related proceedings or investigation.

For additional information regarding this matter, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2009 filed with the SEC on May 29, 2009: Business Information with respect to our Business in General Recent Events Government Regulations , Risk Factors We are subject to extensive regulatory requirements and must receive and maintain regulatory clearance or approval for many products and operations. Failure to receive or maintain, or delays in receiving, clearance or approvals may hurt our revenues, profitability, financial condition or value , Risk Factors We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters , Risk Factors Most of our products, including our new liquid chemical sterilant system, must receive regulatory approvals before they can be marketed and sold in the United States and other countries , and Risk Factors Existing and new Customers may not purchase or use the new liquid chemical sterilant system consistent with the purchase and use of existing STERIS SYSTEM 1[®], and see Item 1A. of Part II.

From time to time, we are also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.

We are subject to taxation from United States federal, state, and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of a statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in note 8 to our consolidated financial statements titled, Income Tax Expense and in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009.

11. Business Segment Information

We operate and report in three business segments: Healthcare, Life Sciences, and Isomedix. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs.

Our Healthcare segment manufactures and sells capital equipment, accessory, consumable, and service solutions to healthcare providers, including acute care hospitals and surgery centers. These solutions aid our Customers in improving the safety, quality, and productivity of their surgical, sterile processing, gastrointestinal, and emergency environments.

Our Life Sciences segment manufactures and sells engineered capital equipment, formulated cleaning chemistries, and service solutions to pharmaceutical companies, and public and private research facilities around the globe.

Our Isomedix segment operates through a network of 20 facilities located in North America. We sell a comprehensive array of contract sterilization services using Gamma Irradiation, Electron Beam Irradiation (E-Beam), and Ethylene Oxide (EO) technologies. We provide sterilization and microbial reduction to companies that supply products to the healthcare, industrial, and consumer products industries. During the third quarter of fiscal 2010, a decision was made to close the Nogales, Arizona facility and exit the E-Beam materials modification business. These actions will occur over the next several months.

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)**

Operating income (loss) for each segment is calculated as the segment's gross profit less direct expenses and indirect cost allocations, which results in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs to the segments. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare segment is responsible for the management of all but one manufacturing facility and uses standard cost to sell products to the Life Sciences segment. Corporate and other includes the gross profit and direct expense of the Defense and Industrial business unit, as well as certain unallocated corporate costs. These costs include executive office costs, Board of Directors compensation, shareholder services and investor relations, external audit fees and legacy pension and postretirement benefit costs from our former Erie manufacturing operations.

The accounting policies for reportable segments are the same as those for the consolidated Company. For the three and nine month periods ended December 31, 2009, revenues from a single Customer did not represent ten percent or more of any reportable segment's revenues. Additional information regarding our segments is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009.

Financial information for each of our segments is presented in the following tables:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2009	2008	2009	2008
Revenues:				
Healthcare	\$ 233,277	\$ 230,177	\$ 656,887	\$ 682,078
Life Sciences	58,910	52,787	159,427	157,977
Isomedix	34,987	34,642	105,129	108,476
Total reportable segments	327,174	317,606	921,443	948,531
Corporate and other	658	1,861	4,161	5,628
Total revenues	\$ 327,832	\$ 319,467	\$ 925,604	\$ 954,159
Operating income (loss):				
Healthcare	\$ 45,254	\$ 32,406	\$ 113,722	\$ 94,334
Life Sciences	10,123	7,151	23,442	14,426
Isomedix	6,929	8,453	22,669	26,851
Total reportable segments	62,306	48,010	159,833	135,611
Corporate and other	(2,878)	(2,192)	(7,478)	(7,785)
Total operating income	\$ 59,428	\$ 45,818	\$ 152,355	\$ 127,826

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)****12. Common Shares**

Basic earnings per common share are calculated based upon the weighted average number of common shares outstanding. Restricted share awards that participate in dividends are included in the determination of basic earnings per common share. Diluted earnings per common share are calculated based upon the weighted average number of common shares outstanding plus the dilutive effect of options calculated using the treasury stock method. The following table summarizes common shares and options outstanding used to calculate basic and diluted earnings per common share:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2009	2008	2009	2008
	(shares in thousands)			
Weighted average common shares outstanding basic	58,962	58,660	58,711	58,889
Dilutive effect of options	796	583	570	812
Weighted average common shares outstanding and common share equivalents diluted	59,758	59,243	59,281	59,701

Options to purchase the following number of common shares at the following weighted average exercise prices were outstanding but excluded from the computation of diluted earnings per common share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the common shares during the periods, so including these options would be anti-dilutive:

	Three Months Ended December 31,		Nine Months Ended December 31,	
	2009	2008	2009	2008
	(shares in thousands)			
Number of common share options	567	916	1,134	758

13. Repurchases of Common Shares

We obtained 11,220 of our common shares during the first nine months of fiscal 2010 in connection with stock-based compensation award programs. We did not repurchase any shares under the authorization provided by our Board of Directors. At December 31, 2009, \$203,864 of STERIS common shares remained authorized for repurchase and 10,914,377 common shares were held in treasury.

14. Share-Based Compensation

STERIS has a long-term incentive plan that makes available common shares for grants at the discretion of the Compensation Committee of the Board of Directors to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, and stock appreciation rights. Stock options provide the right to purchase our common shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest over an approximately three-year period. As of December 31, 2009, 3,751,936 shares remain available for grant under the long-term incentive plan.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

We estimate the fair value of share-based awards on the date of the grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee's compensation and benefits.

The following weighted-average assumptions were used for share-based compensation granted during the first nine months of fiscal 2010 and fiscal 2009:

	Fiscal 2010	Fiscal 2009
Risk-free interest rate	1.89%	2.65%
Expected life of options	5.50 years	5.64 years
Expected dividend yield of stock	1.49%	0.86%
Expected volatility of stock	27.96%	27.72%

The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a timeframe similar to that of the expected life of the grant. We applied estimated forfeiture rates of 2.39 percent and 2.86 percent during fiscal 2010 and 2009, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.

Stock option activity for the first nine months of fiscal 2010 is as follows:

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2009	3,695,931	\$ 24.72		
Granted	622,747	23.23		
Exercised	(547,802)	22.37		
Forfeited	(45,929)	26.62		
Canceled	(13,412)	24.80		
Outstanding at December 31, 2009	3,711,535	\$ 24.79	6.09	\$ 13,429
Exercisable at December 31, 2009	2,434,885	\$ 24.04	4.76	\$ 10,128

The aggregate intrinsic value in the table above represents the total pre-tax difference between the \$27.97 closing price of our common shares on December 31, 2009 over the exercise price of the stock option, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our common shares.

Edgar Filing: STERIS CORP - Form 10-Q

The total intrinsic value of stock options exercised during the first nine months of fiscal 2010 and fiscal 2009 were \$5,350 and \$24,348, respectively. Net cash proceeds from the exercise of stock options were \$12,339

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)**

and \$33,254 for the first nine months of fiscal 2010 and fiscal 2009, respectively. An income tax benefit of \$1,927 and \$8,766 was realized from stock option exercises during the first nine months of fiscal 2010 and fiscal 2009, respectively.

The weighted average grant date fair value of option grants was \$5.69 and \$8.74 for the first nine months of fiscal 2010 and fiscal 2009, respectively.

Stock appreciation rights (SARS) were also granted during the first nine months of fiscal 2010. The 47,560 SARS granted carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise. The fair value of the outstanding SARS are revalued at each reporting date and the related expense is adjusted appropriately.

Restricted share and restricted share unit activity for the first nine months of fiscal 2010 is as follows:

	Number of Restricted Shares	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2009	188,671	54,850	\$ 27.31
Granted	116,731		24.03
Vested	(57,996)	(31,850)	24.24
Canceled	(10,475)		26.70
Non-vested at December 31, 2009	236,931	23,000	\$ 26.84

Restricted shares and restricted share units granted were valued based on the closing stock price at the grant date and are estimated to cliff vest over an approximately three-year period based upon the terms of the grants. The value of restricted shares and restricted share units that vested during the first nine months of fiscal 2010 and fiscal 2009 was \$2,093 and \$1,281, respectively, which is calculated as the number of restricted shares and restricted share units vested during the period multiplied by the weighted-average grant date fair value.

We granted 6,800 and 3,300 cash-settled restricted share units in the first nine months of fiscal 2010 and fiscal 2009, respectively.

As of December 31, 2009, there was \$9,243 of total unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 1.68 years.

15. Financial and Other Guarantees

We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets within Accrued expenses and other. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

Table of Contents

STERIS CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)

For the Three and Nine Months Ended December 31, 2009 and 2008

(dollars in thousands, except per share amounts)

Changes in our warranty liability during the first nine months of fiscal 2010 were as follows:

Balance, March 31, 2009	\$ 7,573
Warranties issued during the period	6,050
Settlements made during the period	(7,089)
Balance, December 31, 2009	\$ 6,534

We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within Accrued expenses and other. The liability recorded for such deferred service revenue was \$17,819 and \$17,477 as of December 31, 2009 and March 31, 2009, respectively. Such deferred revenues are then amortized on a straight-line basis over the contract term and recognized as service revenues on the accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues has been excluded from the table presented above.

16. Forward Contracts

From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We also enter into forward contracts to hedge price changes in commodities that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income.

	Balance Sheet Location	Asset Derivatives		Liability Derivatives	
		Fair Value	Fair Value at	Fair Value	Fair Value at
		at December 31, 2009	March 31, 2009	at December 31, 2009	March 31, 2009
Forward contracts	Prepaid & Other	\$ 241	\$	\$	\$
Forward contracts	Accrued expenses and other	\$	\$	\$ 99	\$ 183

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:

Location of gain (loss) recognized in income	Amount of gain (loss) recognized in income Nine months ended December 31, 2009	2008
---	--	------

Edgar Filing: STERIS CORP - Form 10-Q

Foreign currency forward contracts	Selling, general and administrative	\$ 236	\$ (1,969)
Commodity forward contracts	Cost of Revenues	\$ 181	\$

Table of Contents**STERIS CORPORATION AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) (Continued)****For the Three and Nine Months Ended December 31, 2009 and 2008****(dollars in thousands, except per share amounts)****17. Fair Value Measurements**

Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial instruments using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows our financial assets and liabilities accounted for at fair value on a recurring basis at December 31, 2009:

	December 31, 2009	Fair Value Measurements at December 31, 2009 Using		
		Quoted Prices in Active Markets for Identical Assets Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3
Assets:				
Forward contracts (1)	\$ 241	\$	\$ 241	\$
Investments (2)	1,651	1,651		
Liabilities:				
Forward contracts (1)	\$ 99	\$	\$ 99	\$
Deferred compensation plans (2)	1,654	1,654		

- (1) The fair values of forward contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
- (2) We provide a domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options. We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees making deferrals are entitled to receive distributions of their account balances (amounts deferred, together with earnings (losses)).

18. Subsequent Events

We have evaluated events occurring subsequent to December 31, 2009 through February 9, 2010, the date of issuance of these consolidated financial statements, to determine whether they require recognition or disclosure in the consolidated financial statements. Based upon this evaluation, we have determined that no material subsequent events occurred that require recognition or disclosure in the financial statements.

Table of Contents

Report of Independent Registered Public Accounting Firm

Board of Directors and Shareholders

STERIS Corporation

We have reviewed the consolidated balance sheet of STERIS Corporation and subsidiaries as of December 31, 2009, and the related consolidated statements of income for the three-month and nine-month periods ended December 31, 2009 and 2008, and the consolidated statements of cash flows for the nine-month periods ended December 31, 2009 and 2008. These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based upon our review, we are not aware of any material modifications that should be made to the consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of STERIS Corporation and subsidiaries as of March 31, 2009, and the related consolidated statements of income, shareholders' equity and cash flows for the year then ended, not presented herein, and in our report dated May 28, 2009, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying consolidated balance sheet as of March 31, 2009, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Ernst & Young LLP

Cleveland, Ohio

February 9, 2010

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction. In Management's Discussion and Analysis of Financial Condition and Results of Operations (the MD&A), we explain the general financial condition and the results of operations for STERIS including:

what factors affect our business;

what our earnings and costs were in each period presented;

why those earnings and costs were different from the prior periods;

where our earnings came from;

how this affects our overall financial condition; and

where cash will come from to pay for future capital expenditures.

As you read the MD&A, you should refer to information in our consolidated financial statements, including note 10 in the consolidated financial statements contained herein regarding the matter with the FDA, which present the results of our operations for the third quarter and the first nine months of fiscal 2010 and fiscal 2009. It may also be helpful to read the MD&A in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009. In the MD&A, we analyze and explain the period-over-period changes in the specific line items in the Consolidated Statements of Income. Our analysis may be important to you in making decisions about your investments in STERIS.

Financial Measures. In the following sections of the MD&A, we may, at times, refer to financial measures that are not required to be presented in the consolidated financial statements under U.S. GAAP. We sometimes use the following financial measures in the context of this report: backlog; debt-to-total capital; net debt-to-total capital; and days sales outstanding. We define these financial measures as follows:

Backlog We define backlog as the amount of unfilled capital equipment purchase orders at a point in time. We use this figure as a measure to assist in the projection of short-term financial results and inventory requirements.

Debt-to-total capital We define debt-to-total capital as total debt divided by the sum of total debt and shareholders' equity. We use this figure as a financial liquidity measure to gauge our ability to borrow, fund growth, and measure the risk of our financial structure.

Net debt-to-total capital We define net debt-to-total capital as total debt less cash (net debt) divided by the sum of net debt and shareholders' equity. We also use this figure as a financial liquidity measure and to measure the risk of our financial structure.

Days sales outstanding (DSO) We define DSO as the average collection period for accounts receivable. It is calculated as net accounts receivable divided by the trailing four quarters' revenues, multiplied by 365 days. We use this figure to help gauge the quality of accounts receivable and expected time to collect.

In the following sections of MD&A, we may, at times, also refer to financial measures which are considered to be non-GAAP financial measures under the rules of the SEC. Non-GAAP financial measures we may use are as follows:

Free cash flow We define free cash flow as net cash flows provided by operating activities as presented in the Consolidated Statements of Cash Flows less purchases of property, plant, equipment, and intangibles plus proceeds from the sale of property, plant, equipment, and intangibles, which is also presented in the Consolidated Statements of Cash Flows. We use this measure to gauge our ability to fund future growth outside of core operations, repurchase common shares, pay cash dividends, and

Table of Contents

reduce debt. The following table reconciles the calculations of our free cash flow for the nine months ended December 31, 2009 and 2008:

<i>(dollars in thousands)</i>	Nine Months Ended	
	December 31,	
	2009	2008
Net cash provided by operating activities	\$ 158,668	\$ 108,324
Purchases of property, plant, equipment, and intangibles	(29,839)	(29,704)
Proceeds from the sale of property, plant, equipment, and intangibles	574	10,981
Free cash flow	\$ 129,403	\$ 89,601

We may, at times, refer to our results of operations excluding certain transactions or amounts that are non-recurring or are not indicative of future results, in order to provide meaningful comparative analysis between the periods presented. For example, when discussing changes in revenues, we may, at times, exclude the impact of recently completed acquisitions.

We present these financial measures because we believe that understanding these additional factors underlying our performance provides meaningful analysis of our financial performance. These financial measures should not be considered alternatives to measures required by U.S. GAAP. Our calculations of these measures may be different from the calculations of similar measures used by other companies and you should be careful when comparing these financial measures to those of other companies.

Revenues Defined

As required by Regulation S-X under the Securities Exchange Act of 1934 (Regulation S-X), we separately present revenues generated as either product revenues or service revenues on our Consolidated Statements of Income for each period presented. When we discuss revenues, we may, at times, refer to revenues summarized differently than the Regulation S-X requirements. The terminology, definitions, and applications of terms that we use to describe revenues may be different from terms used by other companies. We use the following terms to describe revenues:

Revenues We present revenues net of sales returns and allowances.

Product Revenues We define product revenues as revenues generated from sales of capital equipment, which includes steam and low temperature liquid sterilizers, washing systems, VHP® technology, water stills, and pure steam generators; integrated OR; surgical lights and tables; and the consumable family of products, which includes STERIS SYSTEM 1® consumables, sterility assurance products, skin care products, and cleaning consumables.

Service Revenues We define service revenues as revenues generated from parts and labor associated with the maintenance, repair, and installation of our capital equipment, as well as revenues generated from contract sterilization offered through our Isomedix segment.

Capital Revenues We define capital revenues, a subset of product revenues, as revenues generated from sales of capital equipment, which includes steam and low temperature liquid sterilizers, washing systems, VHP® technology, water stills, and pure steam generators; surgical lights and tables; and integrated OR.

Consumable Revenues We define consumable revenues, a subset of product revenues, as revenues generated from sales of the consumable family of products, which includes STERIS SYSTEM 1® consumables, sterility assurance products, skin care products, and cleaning consumables.

Edgar Filing: STERIS CORP - Form 10-Q

Recurring Revenues We define recurring revenues as consumable revenues and service revenues.

Table of Contents

General Company Overview and Executive Summary

Our mission is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products, and services. Our dedicated employees around the world work together to supply a broad range of solutions by offering a combination of equipment, consumables, and services to healthcare, pharmaceutical, industrial, and governmental Customers.

The bulk of our revenues are derived from the healthcare and pharmaceutical industries. Much of the growth in these industries is driven by the aging of the population throughout the world, as an increasing number of individuals are entering their prime healthcare consumption years, and is dependent upon advancement in healthcare delivery, acceptance of new technologies, government policies, and general economic conditions. In addition, each of our core industries also benefits from specific trends that contribute toward demand. Within healthcare, there is increased concern regarding the level of hospital-acquired infections around the world. The pharmaceutical industry has been impacted by increased regulatory scrutiny of cleaning and validation processes, mandating that manufacturers improve their processes. In the contract sterilization industry, where our Isomedix segment competes, the aging population increases the demand for medical procedures, which increases the consumption of single use medical devices and surgical kits.

Fiscal 2010 third quarter revenues were \$327.8 million representing a 2.6% increase driven primarily by increases in the Healthcare and Life Sciences reportable business segments. Revenues for the first nine months of fiscal 2010 were \$925.6 million, representing a decrease of 3.0% year-over-year, driven primarily by a decline in our Healthcare business segment. Our gross margin percentages were 42.5% and 42.9% for the third quarter and first nine months of fiscal 2010, which was an increase of 370 basis points compared to the same prior year quarter and an increase of 230 basis points from the first nine months of fiscal 2009. Gross margins during both fiscal 2009 periods include pre-tax expenses of \$9.5 million related to our restructuring actions, which are discussed in further detail below and in note 2 to the consolidated financial statements. Gross margins during both fiscal 2010 periods benefited from price increases and lower raw material costs. On a year-to-date basis, gross margins also benefited from favorable foreign currency fluctuations.

Revenues, in the United States, for STERIS SYSTEM 1[®], including capital equipment, sterilant and accessories, parts and service, are approximately 10.0% of total company revenues for the first nine months of both fiscal 2010 and fiscal 2009.

Free cash flow was \$129.4 million in the first nine months of fiscal 2010 compared to \$89.6 million in the prior year first nine months, reflecting an increase in cash earnings during fiscal 2010 and improved cash flow from operating assets and liabilities. Our debt-to-total capital ratio was 29.7% at December 31, 2009 as compared to 22.6% at March 31, 2009, reflecting an additional borrowing of \$100.0 million in the third quarter, and increased operating income. We also declared and paid cash dividends totaling \$2.33 per common share in the first nine months of fiscal 2010 including a special dividend of \$2.00 per common share. In the first nine months of fiscal 2009, we declared and paid cash dividends totaling \$0.22 per common share.

Additional information regarding the Company's fiscal 2010 third quarter and first nine months financial performance is included in the subsection below titled Results of Operations.

Matters Affecting Comparability

Restructuring. During the third quarter and first nine months of fiscal 2010, we did not incur any significant additional pre-tax expenses related to previously announced restructuring actions, and we settled certain obligations for less than originally expected.

Additional information regarding our restructuring actions is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009.

International Operations. Since we conduct operations outside of the United States using various foreign currencies, our operating results are impacted by foreign currency movements relative to the U.S. dollar. During

Table of Contents

the third quarter of fiscal 2010, our revenues were favorably impacted by \$4.8 million, or 1.5%, and income before taxes was unfavorably impacted by \$5.3 million, or 9.3%, as a result of foreign currency movements relative to the U.S. dollar. During the first nine months of fiscal 2010, our revenues were unfavorably impacted by \$5.3 million, or 0.6%, and income before taxes was unfavorably impacted by \$0.1 million as compared to the same prior year period.

Results of Operations

In the following subsections, we discuss our earnings and the factors affecting them for the third quarter and first nine months of fiscal 2010 compared with the same fiscal 2009 periods. We begin with a general overview of our operating results and then separately discuss earnings for our operating segments.

Revenues. The following table contains information regarding our revenues for the third quarter and first nine months of fiscal 2010 and 2009:

<i>(dollars in thousands)</i>	Three Months Ended December 31,			Percent Change	Percent of Total Revenues	
	2009	2008	Change		2009 (1)	2008 (1)
Capital Revenues	\$ 132,541	\$ 129,563	\$ 2,978	2.3%	40.4%	40.6%
Consumable Revenues	81,531	73,745	7,786	10.6%	24.9%	23.1%
Product Revenues	214,072	203,308	10,764	5.3%	65.3%	63.6%
Service Revenues	113,760	116,159	(2,399)	-2.1%	34.7%	36.4%
Total Revenues	\$ 327,832	\$ 319,467	\$ 8,365	2.6%	100.0%	100.0%
Service Revenues	\$ 113,760	\$ 116,159	\$ (2,399)	-2.1%	34.7%	36.4%
Consumable Revenues	81,531	73,745	7,786	10.6%	24.9%	23.1%
Recurring Revenues	195,291	189,904	5,387	2.9%	59.6%	59.4%
Capital Revenues	132,541	129,563	2,978	2.3%	40.4%	40.6%
Total Revenues	\$ 327,832	\$ 319,467	\$ 8,365	2.6%	100.0%	100.0%
United States	\$ 244,067	\$ 250,355	\$ (6,288)	-2.5%	74.4%	78.4%
International	83,765	69,112	14,653	21.2%	25.6%	21.6%
Total Revenues	\$ 327,832	\$ 319,467	\$ 8,365	2.6%	100.0%	100.0%

	Nine Months Ended December 31,			Percent Change	Percent of Total Revenues	
	2009	2008	Change		2009 (1)	2008 (1)
Capital Revenues	\$ 344,390	\$ 379,993	\$ (35,603)	-9.4%	37.2%	39.8%
Consumable Revenues	242,317	222,753	19,564	8.8%	26.2%	23.3%
Product Revenues	586,707	602,746	(16,039)	-2.7%	63.4%	63.2%
Service Revenues	338,897	351,413	(12,516)	-3.6%	36.6%	36.8%
Total Revenues	\$ 925,604	\$ 954,159	\$ (28,555)	-3.0%	100.0%	100.0%
Service Revenues	\$ 338,897	\$ 351,413	\$ (12,516)	-3.6%	36.6%	36.8%
Consumable Revenues	242,317	222,753	19,564	8.8%	26.2%	23.3%
Recurring Revenues	581,214	574,166	7,048	1.2%	62.8%	60.2%

Edgar Filing: STERIS CORP - Form 10-Q

Capital Revenues	344,390	379,993	(35,603)	-9.4%	37.2%	39.8%
Total Revenues	\$ 925,604	\$ 954,159	\$ (28,555)	-3.0%	100.0%	100.0%
United States	\$ 706,165	\$ 736,713	\$ (30,548)	-4.1%	76.3%	77.2%
International	219,439	217,446	1,993	0.9%	23.7%	22.8%
Total Revenues	\$ 925,604	\$ 954,159	\$ (28,555)	-3.0%	100.0%	100.0%

(1) Certain percentages may not calculate precisely due to rounding.

Table of Contents

Quarter over Quarter Comparison

Revenues increased \$8.4 million, or 2.6%, to \$327.8 million for the quarter ended December 31, as compared to \$319.5 million for the comparable prior year quarter. Capital equipment revenues increased \$3.0 million, or 2.3% as a result of increased sales in Canada, Europe, Asia Pacific and the Latin America region offset by a decrease in the United States. Recurring revenues increased 2.9%, with an increase of 10.6% in consumable revenues, and a decrease in service revenues of 2.1%. Consumables growth in the United States and Europe was partially offset by declines in service revenues in the United States.

International revenues increased \$14.7 million, or 21.2%, to \$83.8 million, for the quarter ended December 31, 2009, as compared to \$69.1 million for the comparable prior year quarter. International revenues were favorably affected by increases in capital equipment revenues, which increased 32.2% due to increases within both our Healthcare and Life Science segments. International recurring revenues increased during the third quarter of fiscal 2010 by 9.0%, with increases of 15.5% and 3.1% in consumable and service revenues, respectively.

United States revenues decreased \$6.3 million, or 2.5%, to \$244.1 million, for the quarter ended December 31, 2009, as compared to \$250.4 million for the comparable prior year quarter. The decrease in United States revenues reflects a 9.4% decrease in capital equipment revenues. United States recurring revenues increased 1.6% with a 9.3% increase in consumable revenues partially offset by a decrease of 3.0% in service revenues.

First Nine Months over First Nine Months Comparison

Revenues decreased \$28.6 million, or 3.0%, to \$925.6 million for the first nine months of fiscal 2010, as compared to \$954.2 million during the first nine months of fiscal 2009. Capital equipment revenues decreased 9.4%, primarily driven by weaker demand within the Healthcare business segment in the United States. Recurring revenues increased 1.2% reflecting an increase in consumable revenues of 8.8% offset by a decline of 3.6% in service revenues.

International revenues for the first nine months of fiscal 2010 were \$219.4 million, an increase of \$2.0 million, or 0.9%, as compared to the first nine months of fiscal 2009. Fiscal 2010 year-to-date international revenues were favorably impacted by a 2.5% increase in capital equipment revenues which was offset by a decline of 0.9% in recurring revenues, reflecting a decline in service revenues that more than offset a rise in consumable revenues.

United States revenues for the first nine months of fiscal 2010 were \$706.2 million, a decrease of \$30.5 million, or 4.1%, as compared to the first nine months of fiscal 2009. The fiscal 2010 year-to-date decrease in United States revenues was primarily driven by a 16.4% decrease in capital equipment revenues in our Healthcare segment. United States recurring revenues grew 1.7% as an 11.0% growth in consumable revenues was partially offset by a 3.6% decline in service revenues. The service revenues decline included a reduction in revenues resulting from the sale, in fiscal 2009 of two Isomedix facilities.

Revenues are further discussed on a segment basis in the section of MD&A titled, Business Segment Results of Operations.

Table of Contents

Gross Profit. The following table compares our gross profit for the three and nine month periods ended December 31, 2009 to the three and nine month periods ended December 31, 2008:

<i>(dollars in thousands)</i>	Three Months Ended December 31,		Change	Percent Change
	2009	2008		
Gross Profit:				
Product	\$ 91,748	\$ 76,197	\$ 15,551	20.4%
Service	47,735	47,870	(135)	-0.3%
Total Gross Profit	\$ 139,483	\$ 124,067	\$ 15,416	12.4%
Gross Profit Percentage:				
Product	42.9%	37.5%		
Service	42.0%	41.2%		
Total Gross Profit Percentage	42.5%	38.8%		

	Nine Months Ended December 31,		Change	Percent Change
	2009	2008		
Gross Profit:				
Product	\$ 254,148	\$ 241,845	\$ 12,303	5.1%
Service	142,826	145,086	(2,260)	-1.6%
Total Gross Profit	\$ 396,974	\$ 386,931	\$ 10,043	2.6%
Gross Profit Percentage:				
Product	43.3%	40.1%		
Service	42.1%	41.3%		
Total Gross Profit Percentage	42.9%	40.6%		

Our gross profit (margin) is affected by the volume, pricing, and mix of our products and services, as well as the costs associated with the products and services that are sold. Gross margin for the third quarter of fiscal 2010 amounted to 42.5%, representing an increase of 370 basis points as compared to the same prior year period. For the first nine months of fiscal 2010, gross margin amounted to 42.9%, representing an increase of 230 basis points as compared to the same prior year period. Gross margins during both the third quarter and first nine months of fiscal 2009 included pre-tax expenses of \$9.5 million related to our restructuring actions. Gross margins during both fiscal 2010 periods benefited from price increases and lower raw material costs. On a year-to-date basis, gross margins also benefited from favorable foreign currency fluctuations.

Operating Expenses. The following table compares our operating expenses for the three and nine month periods ended December 31, 2009 to the three and nine month periods ended December 31, 2008:

<i>(dollars in thousands)</i>	Three Months Ended December 31,		Change	Percent Change
	2009	2008		
Operating Expenses:				
Selling, General, and Administrative	\$ 71,776	\$ 67,272	\$ 4,504	6.7%
Research and Development	8,265	8,122	143	1.8%
Restructuring Expense	14	2,855	(2,841)	NM

Total Operating Expenses	\$ 80,055	\$ 78,249	\$ 1,806	2.3%
---------------------------------	-----------	-----------	----------	------

Table of Contents

	Nine Months Ended		Change	Percent Change
	2009	December 31, 2008		
Operating Expenses:				
Selling, General, and Administrative	\$ 220,897	\$ 231,910	\$ (11,013)	-4.7%
Research and Development	24,035	24,469	(434)	-1.8%
Restructuring Expense	(313)	2,726	(3,039)	NM
Total Operating Expenses	\$ 244,619	\$ 259,105	\$ (14,486)	-5.6%

NM - Not Meaningful

Significant components of total selling, general, and administrative expenses (SG&A) are compensation and benefit costs, fees for professional services, travel and entertainment, facilities costs, and other general and administrative expenses. As a percentage of total revenues, SG&A increased 80 basis points to 21.9% for the third quarter of fiscal 2010 and decreased 40 basis points to 23.9% for the first nine months of fiscal 2010, as compared to the same prior year periods. Both fiscal 2009 periods include a reduction of \$7.9 million resulting from a prior year change in our paid time off benefits. Also included in the first nine months of fiscal 2009 is a \$2.1 million gain on the sale of an Isomedix facility located in the Chicago, Illinois area to a Customer. Both fiscal 2010 periods reflect improved operating expense leverage and the benefit of efficiency initiatives previously implemented.

As a percentage of total revenues, research and development expenses were 2.5% and 2.6% for the three and nine month periods ended December 31, 2009, as compared to 2.5% and 2.6%, respectively, for the same prior year periods. For the three month period ended December 31, 2009, research and development expenses increased 1.8% to \$8.3 million as compared to \$8.1 million during the same prior year period. For the first nine months of fiscal 2010, research and development expenses decreased 1.8% to \$24.0 million, as compared to \$24.5 million, during the same prior year period. The fiscal 2010 period includes a government subsidy of \$0.8 million received for research and development expenses incurred by one of our international locations. Research and development expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological innovations. During the third quarter and first nine months of fiscal 2010, our investments in research and development continued to be focused on, but were not limited to, enhancing capabilities of new chemistries and delivery systems for disinfection and sterilization, sterile processing combination technologies, surgical tables and accessories, and the areas of emerging infectious agents such as Prions and Nanobacteria.

Our operating expenses include restructuring expenses. We recognize restructuring expenses as incurred. In addition, we assess the property, plant and equipment associated with the related facilities for impairment.

The total pre-tax restructuring expenses recorded during the third quarter and first nine months of fiscal 2010 and fiscal 2009 are summarized in the following tables:

(dollars in thousands)

	Fiscal 2009 Restructuring Plan (1)
<i>Three Months Ended December 31, 2009</i>	
Severance, payroll, and other related costs	\$ (23)
Product rationalization	(232)
Lease termination obligations and other	18
Asset impairment	9
Total restructuring charges	\$ (228)

(1) Includes \$(242) in charges recorded in cost of revenues on Consolidated Statements of Income.

Table of Contents

	Fiscal 2009 Restructuring Plan	Fiscal 2008 Restructuring Plan	Total
<i>Three Months Ended December 31, 2008</i>			
Severance, payroll, and other related costs	\$ 3,362	\$ (107)	\$ 3,255
Asset impairment and accelerated depreciation	1,112	(83)	1,029
Product rationalization	9,100	(528)	8,572
Lease termination obligations		(17)	(17)
Other	113	(609)	(496)
Total restructuring charges	\$ 13,687	\$ (1,344)	\$ 12,343

	Fiscal 2009 Restructuring Plan (2)
<i>Nine Months Ended December 31, 2009</i>	
Severance, payroll, and other related costs	\$ (36)
Product rationalization	(466)
Lease termination obligations and other	(290)
Asset impairment	(5)
Total restructuring charges	\$ (797)

(2) Includes \$(484) in charges recorded in cost of revenues on Consolidated Statements of Income.

	Fiscal 2009 Restructuring Plan	Fiscal 2008 Restructuring Plan	European Restructuring Plan	Fiscal 2006 Restructuring Plan	Total
<i>Nine Months Ended December 31, 2008</i>					
Severance, payroll, and other related costs	\$ 3,362	\$ (191)	\$	\$ (178)	\$ 2,993
Asset impairment and accelerated depreciation	1,112	(83)			1,029
Product rationalization	9,100	(523)			8,577
Lease termination obligations		20	99		119
Other	113	(609)			(496)
Total restructuring charges	\$ 13,687	\$ (1,386)	\$ 99	\$ (178)	\$ 12,222

Liabilities related to our restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within Accrued payroll and other related liabilities and Accrued expenses and other. The following table summarizes our liabilities related to these restructuring activities:

	Fiscal 2009 Restructuring Plan Fiscal 2010			
<i>(dollars in thousands)</i>	March 31, 2009	Provision	Payments/ Impairments	December 31, 2009
Severance and termination benefits	\$ 1,920	\$ (36)	\$ (1,690)	\$ 194
Product rationalization	75	(466)	391	
Lease termination obligations and other	578	(290)	(245)	43
Asset impairment		(5)	5	
Total	\$ 2,573	\$ (797)	\$ (1,539)	\$ 237

Table of Contents

	Fiscal 2008 Restructuring Plan Fiscal 2010			
	March 31, 2009	Provision	Payments/ Impairments	December 31, 2009
Severance and termination benefits	\$ 501	\$	\$ (392)	\$ 109
Asset impairments	409		(120)	289
Lease termination obligations and other	881		(392)	489
Total	\$ 1,791	\$	\$ (904)	\$ 887

Non-Operating Expenses, Net. Non-operating expenses (income), net consists of interest expense on debt, offset by interest earned on cash, cash equivalents, short-term investment balances, and other miscellaneous income. The following table compares our non-operating expenses (income), net for the three and nine month periods ended December 31, 2009 to the three and nine month periods ended December 31, 2008:

<i>(dollars in thousands)</i>	Three Months Ended December 31,			Change
	2009	2008		
Non-Operating Expenses (Income):				
Interest Expense	\$ 3,291	\$ 3,214		\$ 77
Interest and Miscellaneous Income	(535)	(366)		(169)
Total Non-Operating Expenses, Net	\$ 2,756	\$ 2,848		\$ (92)

<i>(dollars in thousands)</i>	Nine Months Ended December 31,			Change
	2009	2008		
Non-Operating Expenses (Income):				
Interest Expense	\$ 9,504	\$ 7,499		\$ 2,005
Interest and Miscellaneous Income	(1,031)	(1,288)		257
Total Non-Operating Expenses, Net	\$ 8,473	\$ 6,211		\$ 2,262

Interest expense increased \$0.1 million and \$2.0 million during the third quarter and first nine months of fiscal 2010, respectively, as compared to the same prior year periods as a result of higher average debt levels during both fiscal 2010 periods. Interest and miscellaneous income increased \$0.2 million for the third quarter and decreased \$0.3 million the first nine months of fiscal 2010, as compared to same prior year periods.

Income Tax Expense. The following table compares our income tax expense and effective income tax rates for the three and nine month periods ended December 31, 2009 to the three and nine month periods ended December 31, 2008:

<i>(dollars in thousands)</i>	Three Months Ended December 31,			Percent Change
	2009	2008	Change	
Income Tax Expense	\$ 15,666	\$ 14,395	\$ 1,271	8.8%
Effective Income Tax Rate	27.6%	33.5%		
<i>(dollars in thousands)</i>	Nine Months Ended December 31,			Percent Change
	2009	2008	Change	
Income Tax Expense	\$ 45,250	\$ 38,746	\$ 6,504	16.8%
Effective Income Tax Rate	31.4%	31.9%		

Edgar Filing: STERIS CORP - Form 10-Q

Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates from continuing operations for the three and nine

Table of Contents

month periods ended December 31, 2009 were 27.6% and 31.4%, respectively, as compared to 33.5% and 31.9%, respectively, for the same prior year periods. The lower effective income tax rate for the third quarter of fiscal 2010 resulted principally from discrete item adjustments and tax planning initiatives.

We record income tax expense during interim periods based on our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. We analyze various factors to determine the estimated annual effective income tax rate, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carryforwards, and available tax planning alternatives.

Business Segment Results of Operations. We operate and report in three business segments: Healthcare, Life Sciences, and Isomedix. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs. Our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009, provides additional information about each business segment. The following table compares business segment revenues for the three and nine month periods ended December 31, 2009 to the three and nine month periods ended December 31, 2008:

<i>(dollars in thousands)</i>	Three Months Ended			Percent Change
	December 31,		Change	
	2009	2008		
Revenues:				
Healthcare	\$ 233,277	\$ 230,177	\$ 3,100	1.3%
Life Sciences	58,910	52,787	6,123	11.6%
Isomedix	34,987	34,642	345	1.0%
Total reportable segments	327,174	317,606	9,568	3.0%
Corporate and other	658	1,861	(1,203)	-64.6%
Total Revenues	\$ 327,832	\$ 319,467	\$ 8,365	2.6%

	Nine Months Ended			Percent Change
	December 31,		Change	
	2009	2008		
Revenues:				
Healthcare	\$ 656,887	\$ 682,078	\$ (25,191)	-3.7%
Life Sciences	159,427	157,977	1,450	0.9%
Isomedix	105,129	108,476	(3,347)	-3.1%
Total reportable segments	921,443	948,531	(27,088)	-2.9%
Corporate and other	4,161	5,628	(1,467)	-26.1%
Total Revenues	\$ 925,604	\$ 954,159	\$ (28,555)	-3.0%

Healthcare Segment

Healthcare segment revenues represented 71.2% of total revenues for the third quarter of fiscal 2010 compared with 72.1% for the same prior year period. Healthcare revenues increased \$3.1 million, or 1.3%, to \$233.3 million for the quarter ended December 31, 2009, compared with \$230.2 million for the third quarter of the prior year. Consumable revenues increased 10.4% for the quarter ended December 31, 2009 because of increased demand for our products. This increase was partially offset by declines in revenues from capital equipment and service of 2.2% and 1.3%, respectively. At December 31, 2009, the Healthcare segment's backlog amounted to \$134.4 million, increasing \$4.5 million, or 3.4%, compared to the backlog of \$129.9 million at September 30, 2009 and increasing \$0.5 million, or 0.4%, compared to the backlog of \$133.9 million at December 31, 2008.

Table of Contents

Healthcare segment revenues represented 71.0% of total revenues for the first nine months of fiscal 2010 compared with 71.5% for the same prior year period. Healthcare revenues decreased \$25.2 million, or 3.7%, to \$656.9 million for the nine months ended December 31, 2009, as compared to \$682.1 million for the same prior year period. The decrease is attributed to lower capital equipment and service revenues, which decreased 10.5% and 3.4%, respectively, primarily due to declines within the United States. Consumable revenues grew 7.9%, primarily within the United States and Europe.

Life Sciences Segment

Life Sciences segment revenues represented 18.0% of total revenues for the third quarter of fiscal 2010 compared with 16.5% for the same prior year period. Life Sciences revenues increased \$6.1 million, or 11.6%, to \$58.9 million for the quarter ended December 31, 2009, as compared to \$52.8 million for the third quarter of the prior year. Capital revenues grew 26.6% with increases in Canada, Europe and Latin America. Interim capital revenues within the Life Sciences segment can be impacted by various factors including the status of customer projects and production lead times. Consumables revenues increased 11.2%. These increases were slightly offset by a decrease in service revenues of 4.2%. At December 31, 2009, the Life Sciences segment's backlog amounted to \$45.4 million, a decrease of \$1.1 million, or 2.4%, compared to the backlog of \$46.5 million at September 30, 2009 and a decrease of \$4.8 million, or 9.6%, compared to the backlog of \$50.2 million at December 31, 2008.

Life Sciences segment revenues represented 17.2% of total revenues for the first nine months of fiscal 2010, compared with 16.6% for the same prior year period. Life Sciences revenues increased \$1.5 million, or 0.9%, to \$159.4 million for the first nine months of fiscal 2010, as compared to \$158.0 million for the same prior year period. The increase in Life Sciences revenues was primarily driven by a 13.2% increase in consumable revenues reflecting increases in United States and Europe. The increase was offset by decreases in both capital equipment and service revenues of 3.3% and 3.1%, respectively. Capital equipment revenues continue to be impacted by project delays, by our pharmaceutical and research Customers.

Isomedix Segment

Isomedix segment revenues represented 10.7% of total revenues for the third quarter of fiscal 2010, compared with 10.8% for the comparable prior year quarter. The segment's revenues increased \$0.3 million, or 1.0% to \$35.0 million during the third quarter of fiscal 2010, as compared to \$34.6 million during the comparable prior year quarter.

Isomedix segment revenues represented 11.4% of total revenues for the first nine months of fiscal 2010 compared with 11.4% for the comparable prior year period. The segment experienced decreased revenues of \$3.3 million, or 3.1%, to \$105.1 million during the first nine months of fiscal 2010 as compared to \$108.5 million for the same prior year period. Revenues were affected by the previously disclosed sale of two facilities during fiscal 2009, which were partially offset by a modest improvement in demand from medical device customers.

The following table compares our business segment operating results for the three and nine month periods ended December 31, 2009 to the three and nine month periods ended December 31, 2008:

<i>(dollars in thousands)</i>	Three Months Ended		Change	Percent Change
	2009	December 31, 2008		
Operating income (loss):				
Healthcare	\$ 45,254	\$ 32,406	\$ 12,848	39.6%
Life Sciences	10,123	7,151	2,972	41.6%
Isomedix	6,929	8,453	(1,524)	-18.0%
Total reportable segments	62,306	48,010	14,296	29.8%
Corporate and other	(2,878)	(2,192)	(686)	NM
Total Operating Income	\$ 59,428	\$ 45,818	\$ 13,610	29.7%

Table of Contents

	Nine Months Ended December 31,		Change	Percent Change
	2009	2008		
Operating income (loss):				
Healthcare	\$ 113,722	\$ 94,334	\$ 19,388	20.6%
Life Sciences	23,442	14,426	9,016	62.5%
Isomedix	22,669	26,851	(4,182)	-15.6%
Total reportable segments	159,833	135,611	24,222	17.9%
Corporate and other	(7,478)	(7,785)	307	NM
Total Operating Income	\$ 152,355	\$ 127,826	\$ 24,529	19.2%

NM- Not meaningful

Operating income (loss) for each segment is calculated as the segment's gross profit less direct expenses and indirect cost allocations, which results in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs to the segments. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare segment is responsible for the management of all but one manufacturing facility and uses standard cost to sell products to the Life Sciences segment. Corporate and other includes the gross profit and direct expense of the Defense and Industrial business unit, as well as certain unallocated corporate costs. These costs include executive office costs, Board of Directors compensation, shareholder services and investor relations, external audit fees and legacy pension and postretirement benefit costs from our former Erie manufacturing operations.

Healthcare Segment

The Healthcare segment's operating income increased \$12.8 million and \$19.4 million for the third quarter and first nine months of fiscal 2010, respectively, as compared to the same prior year periods. The segment's operating margins were 19.4% and 17.3% for the third quarter and first nine months of fiscal 2010, respectively, representing increases of 530 basis points and 350 basis points, respectively, as compared to prior year periods. The Healthcare segment's operating income for the third quarter and first nine months of fiscal 2009 include \$10.0 million and \$9.8 million in pre-tax expenses, respectively, related to our restructuring actions. Both fiscal 2009 periods also include a pre-tax benefit of \$5.9 million resulting from the change in our benefit policy related to paid time off. The improvement in operating income was driven by operating efficiencies and lower raw material costs.

Life Sciences Segment

The Life Sciences segment's operating income increased \$3.0 million and \$9.0 million for the third quarter and first nine months of fiscal 2010, respectively, as compared to the same prior year periods. The segment's operating margins were 17.2% and 14.7% for the third quarter and first nine months of fiscal 2010, respectively, representing increases of 370 basis points and 560 basis points, respectively, over the comparable prior year periods. The Life Sciences segment's operating income for both fiscal 2009 periods includes pre-tax expenses of \$2.4 million related to our restructuring actions. Both fiscal 2009 periods also include a pre-tax benefit of \$1.2 million resulting from the change in our benefit policy related to paid time off. The improvement in year over year operating income was primarily driven by operating efficiencies.

Isomedix Segment

The Isomedix segment's operating income decreased \$1.5 million and \$4.2 million for the third quarter and first nine months of fiscal 2010, respectively, as compared to the same prior year periods. The segment's operating margins were 19.8% and 21.6% for the third quarter and first nine months of fiscal 2010, representing decreases of 460 basis points and 320 basis points, respectively, over the comparable prior year periods. During

Table of Contents

both fiscal 2009 periods, the Isomedix segment's operating margins include a pre-tax benefit of \$0.8 million resulting from the change in our benefit policy related to paid time off. Included in the segment's operating income for the first nine months of fiscal 2009 is a \$2.1 million pre-tax gain on the sale of a facility located in the Chicago, Illinois area to a Customer. During the third quarter of fiscal 2010, decisions were made to close the Nogales, Arizona facility and exit the E-Beam materials modification business resulting in pre-tax expense of \$1.7 million. Annualized revenues will be reduced by approximately \$1.0 million as a result of these decisions.

Liquidity and Capital Resources. The following table summarizes significant components of our cash flows for the nine months ended December 31, 2009 and 2008:

Cash Flows

<i>(dollars in thousands)</i>	Nine Months Ended December 31,	
	2009	2008
Operating activities:		
Net income	\$ 98,632	\$ 82,869
Non-cash items	54,304	50,606
Changes in operating assets and liabilities	5,732	(25,151)
Net cash provided by operating activities	\$ 158,668	\$ 108,324
Investing activities:		
Purchases of property, plant, equipment, and intangibles	\$ (29,839)	\$ (29,704)
Proceeds from the sale of property, plant, equipment, and intangibles	574	10,981
Equity investments in joint venture	(1,500)	(4,150)
Net cash used in investing activities	\$ (30,765)	\$ (22,873)
Financing activities:		
Proceeds from the issuance of long-term obligations	\$	\$ 150,000
Payments on long-term obligations		(40,500)
Proceeds (payments) under credit facilities, net	100,000	(79,180)
Deferred financing fees and debt issuance costs		(476)
Repurchases of common shares	(289)	(80,466)
Cash dividends paid to common shareholders	(137,509)	(12,981)
Stock option and other equity transactions, net	12,339	33,254
Tax benefit from stock options exercised	1,927	8,766
Net cash used in financing activities	\$ (23,532)	\$ (21,583)
Debt-to-total capital ratio	29.7%	22.7%
Net debt-to-total capital ratio	5.7%	7.2%
Free cash flow	\$ 129,403	\$ 89,601

Net Cash Provided by Operating Activities. The net cash provided by our operating activities was \$158.7 million for the first nine months of fiscal 2010 compared with \$108.3 million for the first nine months of fiscal 2009. The following discussion summarizes the significant changes in our operating cash flows:

Non-cash items Our non-cash items include depreciation, depletion, and amortization, deferred income taxes, share-based compensation expense, loss (gain) on disposal of property, plant, equipment and intangibles and other items. Non-cash items were \$54.3 million for the first nine months of fiscal 2010 compared with \$50.6 million for the first nine months of fiscal 2009. Significant changes in these items for the first nine months of fiscal 2010 as compared to the same prior year period are summarized below:

Edgar Filing: STERIS CORP - Form 10-Q

Depreciation, depletion, and amortization Depreciation, depletion, and amortization are the most significant component of non-cash items. This expense totaled \$42.0 million and \$43.9 million for the first nine months of fiscal 2010 and 2009, respectively.

Table of Contents

Deferred income taxes Our deferred income tax benefits decreased \$1.2 million for the first nine months of fiscal 2010, compared with an increase of \$10.9 million for the first nine months of fiscal 2009 due to the timing and recognition of settlements and changes in provisions.

Loss (gain) on the disposal of property, plant, equipment, and intangibles During the first nine months of fiscal 2010, we recorded a loss of \$1.5 million for the disposal of property, plant, equipment, and intangibles, compared with a gain of \$1.4 million for the same prior year period. Included in the loss recorded during the first nine months of fiscal 2010 is the cost associated with the decision to exit the E-beam materials modification business, which represented a small portion of Isomedix revenues. Included in the gain during the first nine months of fiscal 2009 is the \$2.1 pre-tax gain on the sale of an Isomedix facility in the Chicago, Illinois area to a Customer, partially offset by asset impairments related to the Fiscal 2009 Restructuring Plan.

Other items Other items amounted to \$4.0 million for the first nine months of fiscal 2010 as compared to a negative \$8.3 million for the first nine months of fiscal 2009. The year over year change primarily reflects a \$7.9 million non-cash adjustment as a result of a change in our benefit policy with respect to paid time off and an estimated curtailment gain related to our Switzerland defined benefit pension plan included in the fiscal 2009 period.

Changes in operating assets and liabilities Changes to our operating assets and liabilities amounted to a positive \$5.7 million and a negative \$25.2 million during the first nine months of fiscal 2010 and fiscal 2009, respectively. Significant changes in the first nine months of fiscal 2010 as compared to the first nine months of fiscal 2009 are summarized below:

Accounts receivable, net Changes in our net accounts receivable balances provided cash of \$38.1 million and \$25.7 million during the first nine months of fiscal 2010 and fiscal 2009, respectively. Our accounts receivable balances may change from period to period due to the timing of revenues and customer payments.

Inventories, net Decreases in our net inventory balances provided cash of \$9.3 million for the first nine months of fiscal 2010 whereas increases in our net inventory balance drove uses of cash of \$12.8 million during the first nine months of fiscal 2009. Inventory balances in fiscal 2010 reflect reductions in inventory levels and lower raw material costs.

Prepaid expenses and other current assets Our other current assets primarily consist of prepaid expenses for insurance, taxes, and other general corporate items. Changes in our other current asset balances provided cash of \$3.4 million and \$10.7 million for the first nine months of fiscal 2010 and 2009, respectively.

Accounts payable, net Decreases in our net accounts payable balances drove uses of cash of \$14.8 million and \$13.3 million during the first nine months of fiscal 2010 and fiscal 2009, respectively. Cash flows related to accounts payable may change from period to period due to varying payment due dates and other terms of our accounts payable obligations.

Accruals and other, net Changes in our net accruals and other liabilities balances drove uses of cash of \$30.1 million and \$35.5 million during the first nine months of fiscal 2010 and fiscal 2009, respectively. The higher cash usage in the first nine months of fiscal 2009 primarily reflects payments made in fiscal 2009 against amounts accrued in fiscal 2008 for incentive compensation and severance, and the payment of income taxes previously accrued. Cash flows related to our accruals and other liabilities balances will change from period to period due to the timing of accruals and payments under our incentive compensation programs. Accruals under our various incentive compensation programs rise during the course of the fiscal year and decline significantly in the first fiscal quarter as payments are made under these programs. Changes in accruals for deferred revenues also contribute to the increase or decrease in these balances.

Table of Contents

Net Cash Used In Investing Activities. The net cash we used in investing activities totaled \$30.8 million for the first nine months of fiscal 2010 compared with \$22.9 million for the first nine months of fiscal 2009. The following discussion summarizes the significant changes in our investing cash flows for the first nine months of fiscal 2010 as compared to the first nine months of fiscal 2009:

Purchases of property, plant, equipment, and intangibles Capital expenditures were \$29.8 million for the first nine months of fiscal 2010 compared with \$29.7 million during the same prior year period.

Proceeds from the sale of property, plant, equipment, and intangibles During the first nine months of fiscal 2010, we recorded proceeds of \$0.6 million. During the prior year, we recorded proceeds of \$11.0 million of which \$9.5 million related to the sale of an Isomedix facility located in the Chicago, Illinois area to a Customer and \$1.5 million related to a settlement of an insurance claim.

Equity investment in joint venture During the third quarter of fiscal 2010 and fiscal 2009, we invested \$1.5 million and \$4.2 million, respectively, in a joint venture with VTS Medical Systems Inc. designed to bring the latest high-definition video, touch-screen integration, and communication technology into hospital operating rooms.

Net Cash Used In Financing Activities. The net cash used in financing activities totaled \$23.5 million for the first nine months of fiscal 2010 compared with \$21.6 million for the first nine months of fiscal 2009. The following discussion summarizes the significant changes in our financing cash flows for the first nine months of fiscal 2010 as compared to the first nine months of fiscal 2009:

Proceeds from the issuance of long-term obligations We issued \$150.0 million of senior notes during the first nine months of fiscal 2009 in an offering that was exempt from the registration requirements of the Securities Act of 1933. Proceeds from the senior notes issued during the third quarter of fiscal 2009 were used in part to repay amounts outstanding under our revolving credit facility. The senior notes allowed the Company to lock-in favorable long-term rates. Amounts borrowed are generally used to fund common share repurchases and working capital changes, and for other corporate purposes.

Net proceeds under credit facilities We borrowed \$100.0 million under our revolving credit facility during fiscal 2010. The proceeds provide additional liquidity for operations and corporate initiatives. During fiscal 2009, the Company repaid \$79.2 million under our revolving credit facility.

Repurchases of common shares We obtained 11,220 of our common shares during the first nine months of fiscal 2010 in connection with stock-based compensation award programs. During the first nine months of fiscal 2010, we did not repurchase any shares under the authorization provided by our Board of Directors. During the first nine months of fiscal 2009, we paid for the repurchase of 2,646,177 of our common shares at an average purchase price of \$30.41 per common share.

Cash dividends paid to common shareholders During the first nine months of fiscal 2010, we paid cash dividends totaling \$2.33, including a special dividend of \$2.00 per common share. During the first nine months of fiscal 2009, we paid cash dividends of \$0.22 per outstanding common share. Total cash dividends paid during the first nine months of fiscal 2010 and fiscal 2009 amounted to \$137.5 million and \$13.0 million, respectively.

Stock option and other equity transactions, net We receive cash for issuing common shares under our various employee stock option programs. During the first nine months of fiscal 2010 and fiscal 2009, we received cash proceeds totaling \$12.3 million and \$33.3 million, respectively, under these programs.

Edgar Filing: STERIS CORP - Form 10-Q

Tax benefit from stock options exercised During the first nine months of fiscal 2010 and fiscal 2009, our income taxes were reduced by \$1.9 million and \$8.8 million, respectively, as a result of deductions allowed for stock options exercised.

Cash Flow Measures. Free cash flow was \$129.4 million in the first nine months of fiscal 2010 compared to \$89.6 million in the prior year first nine months, reflecting an increase in cash earnings in fiscal 2010 and

Table of Contents

improved cash flow from operating assets and liabilities. Our debt-to-total capital ratio was 29.7% at December 31, 2009 and 22.6% at March 31, 2009. Our net debt-to-total capital ratio was 5.7% at December 31, 2009 and 7.2% at March 31, 2009.

Sources of Credit and Contractual and Commercial Commitments. Information related to our sources of credit and contractual and commercial commitments is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009. Our commercial commitments were approximately \$30.9 million at December 31, 2009 reflecting a net decrease of \$1.6 million in surety bonds and other commercial commitments from March 31, 2009. Except as described, our contractual commitments have not changed materially from March 31, 2009. The maximum aggregate borrowing limits under our revolving credit facility (Facility) have not changed since March 31, 2009. At December 31, 2009, the maximum amount available for borrowing under this Facility was \$275.6 million. The maximum aggregate borrowing limit of \$400.0 million under the Facility is reduced by outstanding borrowings (\$100.0 million at December 31, 2009) and letters of credit issued under a sub-limit within the Facility (\$24.4 million at December 31, 2009). The Facility matures on September 13, 2012.

Cash Requirements. Currently, we intend to use our existing cash and cash equivalent balances, cash generated from operations, and our existing credit facilities for short-term and long-term capital expenditures and our other liquidity needs. We believe that these amounts will be sufficient to meet working capital needs, capital requirements, and commitments for at least the next twelve months. However, our capital requirements will depend on many uncertain factors, including our rate of sales growth, our Customers' acceptance of our products and services, the costs of obtaining adequate manufacturing capacities, the timing and extent of our research and development projects, and changes in our operating expenses. To the extent that our existing sources of cash are not sufficient to fund our future activities, we may need to raise additional funds through additional borrowings or selling equity securities. We cannot assure you that we will be able to obtain additional funds on terms favorable to us, or at all.

Critical Accounting Policies, Estimates, and Assumptions. Information related to our critical accounting policies, estimates, and assumptions is included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009. Our critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2009.

Contingencies. We are involved in various patent, product liability, consumer, commercial, environmental, tax proceedings and claims, governmental investigations, and other legal and regulatory proceedings that arise from time to time in the ordinary course of our business. We record a liability for such contingencies to the extent that we conclude that their occurrence is both probable and estimable. We consider many factors in making these assessments, including the professional judgment of experienced members of management and our legal counsel. We have made estimates as to the likelihood of unfavorable outcomes and the amounts of such potential losses. In our opinion, the ultimate outcome of these proceedings and claims is not anticipated to have a material adverse affect on our consolidated financial position, results of operations, or cash flows. However, the ultimate outcome of claims, litigation, and other proceedings is unpredictable and actual results could be materially different from our estimates. We record anticipated recoveries under applicable insurance contracts when assured of recovery. Refer to Part II, Item 1, Legal Proceedings for additional information.

We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual tax jurisdiction or the closing of a statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. The IRS routinely conducts audits of our federal income tax returns. In the first quarter of fiscal 2009, we reached a settlement with the IRS for all material tax matters for fiscal 2002 through fiscal 2005. In the second quarter of fiscal 2010, we reached a settlement with the IRS on all material tax matters for fiscal 2006 through fiscal 2007. We remain subject to tax authority audits in various other jurisdictions in which we operate.

Table of Contents

If we prevail in matters for which accruals have been recorded, or are required to pay amounts in excess of recorded accruals, our effective income tax rate in a given financial statement period could be materially impacted.

International Operations. Since we conduct operations outside of the United States using various foreign currencies, our operating results are impacted by foreign currency movements relative to the U.S. dollar. During the third quarter of fiscal 2010, our revenues were favorably impacted by \$4.8 million, or 1.5%, and income before taxes was unfavorably impacted by \$5.3 million, or 9.3%, as a result of foreign currency movements relative to the U.S. dollar. During the first nine months of fiscal 2010, our revenues were unfavorably impacted by \$5.3 million, or 0.6%, and income before taxes was unfavorably impacted by \$0.1 million as compared to the same prior year period.

Forward-Looking Statements. This Quarterly Report on Form 10-Q may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry that are intended to qualify for the protections afforded forward-looking statements under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as may, will, expects, believes, anticipates, plans, estimates, projects, targets, forecasts, outlook, impact, potential, confidence, improve, comfortable, trend, and seeks, or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws or government regulations or the application or interpretation thereof. Other risk factors are described herein and in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any outcome from litigation, regulatory action, administrative proceedings, government investigations, warning letters, cost reductions, business strategies, rebate programs, earnings and revenue trends, expense reduction or other future financial results. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that product approvals will not occur or market demand will not develop for new technologies, products or applications (including the new liquid chemical sterilant technology), or the Company's business initiatives will take longer, cost more or produce lower benefits than anticipated, (c) the possibility that claims, litigation, certifications, or other demands, requirements or standards, or the application of or compliance with laws, court rulings, regulations, regulatory actions, including without limitation previously disclosed FDA warning letters, government investigations, and the December 3, 2009 FDA notice, may delay or prevent new product introductions, affect the production and marketing of existing products or otherwise affect Company performance, results, prospects or value, or may require the Company to take other actions, including recalls, to pay significant monetary fines or civil damages, or to be subject to other governmental or third party claims or remedies, which could materially affect our performance, results, prospects or value (d) the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services, (f) the possibility that anticipated revenue, profitability, cost savings, efficiencies, or other results may not be achieved or may be delayed, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the matters described in this report may adversely impact our performance, results, prospects or value, (g) the effect of the contraction in credit availability, as well as the ability of our Customers and suppliers to adequately access the credit markets when needed, and (h) those risks described in our Annual Report on Form 10-K for the year ended March 31, 2009 and this Form 10-Q for the quarter ended December 31, 2009.

Table of Contents

Availability of Securities and Exchange Commission Filings. We make available free of charge on or through our website, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to these reports as soon as reasonably practicable after we file such material with, or furnish such material to, the SEC. You may access these documents on the Investor Relations page of our website at <http://www.steris-ir.com>. The information on our website is not incorporated by reference into this report. You may also obtain copies of these documents by visiting the SEC's Public Reference Room at 100 F Street, NE, Washington, D.C. 20549, or by accessing the SEC's website at <http://www.sec.gov>. You may obtain information on the Public Reference Room by calling the SEC at 1-800-SEC-0330.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we are subject to interest rate, foreign currency, and commodity risks. Information related to these risks and our management of these exposures is included in this Quarterly Report on Form 10-Q in Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations in the subsection titled, Liquidity and Capital Resources. Additional information related to these risks and our management of these exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosures about Market Risk, included in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the SEC on May 29, 2009. Our exposures to market risks have not changed materially since March 31, 2009.

ITEM 4. CONTROLS AND PROCEDURES

Under the supervision of and with the participation of our management, including the Principal Executive Officer (PEO) and Principal Financial Officer (PFO), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as of the end of the period covered by this Quarterly Report. Based on that evaluation, including the assessment and input of our management, the PEO and PFO concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective.

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, that occurred during the quarter ended December 31, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise from the ordinary course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), economic loss (e.g., breach of contract, other commercial claims), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.

We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse affect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations (including without limitation the FDA-related matters discussed below), claims or other proceedings. For certain types of claims, we presently maintain product liability insurance coverage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.

The FDA and the United States Department of Justice had been conducting an investigation to our knowledge since 2003 involving our STERIS SYSTEM 1® sterile processing system. We had received requests for documents, including the subpoena received in January 2005, and were aware of interviews of current and former employees in connection with the investigation. We responded to these requests and cooperated with the government agencies regarding this matter. We were advised by the United States Attorney's Office for the Northern District of Ohio in May 2009 that it was declining to pursue the investigation.

On May 16, 2008, we received a warning letter (the "warning letter") from the FDA regarding our STERIS SYSTEM® sterile processor and the STERIS 20 sterilant used with the processor (sometimes referred to collectively in the FDA letter and in this Item 1 as the "device"). We believe this warning letter arose from the previously disclosed investigation. In summary, the warning letter included the FDA's assertion that significant changes or modifications have been made in the design, components, method of manufacture, or intended use of the device beyond the FDA's 1988 clearance, such that the FDA believes a new premarket notification submission (known within FDA regulations as a 510(k) submission) should have been made. The warning letter referenced a number of changes to the device that, according to the FDA, require a new premarket notification submission, and asserted that our failure to make such a submission resulted in violations of applicable law. The warning letter also requested documentation and explanation regarding various corrective actions related to the device prior to 2003, and whether those actions should be considered corrections or removals requiring notice under applicable FDA regulations. On July 30, 2008 (with an Addendum on October 9, 2008), we provided a detailed response contending that the assertions in the warning letter were not correct.

On November 4, 2008, we received a letter from the FDA (dated November 3, 2008) in which the FDA stated without elaboration that, after reviewing our response, it disagreed with our position and that a new premarket notification submission is required. The agency did not address the removal and correction reporting issues and invited a meeting with STERIS to discuss the warning letter, based on our earlier request. After

Table of Contents

discussions with the FDA regarding the November 3rd letter, we received an additional letter on November 6, 2008 from the FDA. The November 6th letter stated that the intent of the November 3rd letter was to inform us of the FDA's preliminary disagreement with our response to the warning letter and, before finalizing a position, the FDA reiterated that it wanted to meet with us to discuss the Company's response, issues related to the warning letter and next steps to resolve any differences between the Company and the FDA.

We thereafter met with the FDA and, on January 20, 2009, we announced that we submitted to the FDA a new liquid chemical sterilant system for 510(k) clearance. The new submission followed discussions with the FDA regarding the prior 510(k) submission issues raised in the warning letter related to our existing device. We believe the new liquid chemical sterilant system submitted to the FDA addresses the changes referenced by the FDA in the warning letter and includes additional technology updates. We have no assurance the FDA will clear the new system for sale or that the system will receive market acceptance. Also in the January 20, 2009 announcement, based on discussion with the FDA, we communicated to Customers that we would continue supporting the existing STERIS SYSTEM 1® installed base by providing accessories, sterilant, service and parts, and replacement processor units for at least a two year period.

On December 3, 2009, the FDA provided a notice (notice) to healthcare facility administrators and infection control practitioners describing FDA's concerns about the STERIS SYSTEM 1 Processor, components and accessories, and FDA recommendations. In that notice, FDA stated its belief that the STERIS SYSTEM 1 device had been significantly modified, that FDA had not cleared or approved the modified device, and that FDA has not determined whether the STERIS SYSTEM 1® is safe or effective for its labeled claims. The notice further stated that use of a device that does not properly sterilize or disinfect a medical or surgical device poses risks to patients and users, including the transmission of pathogens, exposure to hazardous chemicals and affect on the quality and functionality of reprocessed instruments. The notice stated that FDA was aware of reports of malfunctions of the STERIS SYSTEM 1® that had the potential to cause or contribute to serious injuries to patients, such as infections, or injuries to healthcare staff, such as burns. Included in FDA's December 3, 2009 notice was a recommendation from FDA that if users had acceptable alternatives to meet sterilization and disinfection needs, users should transition to that alternative as soon as possible. On December 10, 2009, the FDA stated its belief that Customers should be able to transition from STERIS SYSTEM 1 within three to six months.

Since the December 3, 2009 notice, the FDA has engaged in discussions with healthcare providers, professional organizations, STERIS and others regarding this notice, its impact on users, the process of transition, acceptable alternatives, considerations for healthcare providers concerning continued use of and transition from STERIS SYSTEM 1, and the timing of such transition. On February 2, 2010, the FDA updated its December 10, 2009 information by extending to 18 months the total recommended time period for transitioning from SYSTEM 1 to acceptable alternative devices. We have continued to provide accessories, sterilant, service, and parts for STERIS SYSTEM 1 pursuant to FDA's enforcement discretion. At this time, we also are continuing discussions with FDA regarding possible resolution of this matter. On February 5, 2010, a complaint was filed by a Customer who claims to have purchased two STERIS SYSTEM 1 devices from STERIS. *Physicians of Winter Haven LLC d/b/a Day Surgery Center v. Steris Corp.*, Case No. 1:1-cv-00264-CAB (N.D. Ohio). The complaint alleges statutory violations, breaches of various warranties, negligence, failure to warn, and unjust enrichment. Plaintiff seeks class certification, damages, and other legal and equitable relief including, without limitation, attorneys' fees and an order requiring STERIS to replace, recall or adequately repair the product and/or to take appropriate regulatory action. We are evaluating this matter and expect to defend against these allegations.

There is no assurance that discussions with FDA will continue, that a resolution will be reached, that enforcement discretion will continue, that other lawsuits will not be brought, that the FDA or third party claimants will not pursue judicial, administrative or other legal or enforcement action or seek other remedies, including a recall or an immediate demand that we stop further sales of the SYSTEM 1 device and any related accessories, services and sterilant, product replacement, or damages, or take other action as described in this

Table of Contents

Item, in the Item entitled "Risk Factors" contained in this Form 10-Q or in our Annual Report on Form 10-K for the year ended March 31, 2009, filed with the Securities and Exchange Commission ("SEC") on May 29, 2009.

We continue to believe that the changes described in the warning letter and the notice from the FDA do not significantly affect the safety or effectiveness of the device and, therefore, did not and do not require a new premarket notification submission, and further, that the corrective actions also described in the warning letter were compliant with FDA regulations. However, if the FDA's assertions are ultimately determined to be correct, the device would be considered adulterated and misbranded under United States law, in which case, we would be required to make a new premarket notification submission. The FDA also could take enforcement action immediately without providing the opportunity to make a new 510(k) submission. If we did not make that 510(k) submission, if the FDA rejected that 510(k) submission, if the FDA took immediate enforcement action or if governmental agencies and/or third parties otherwise considered the device to be non-compliant, civil, administrative, or criminal proceedings could be initiated. These or other proceedings involving our STERIS SYSTEM 1[®] sterile processing system and STERIS[™] 20 sterilant, a significant product to us, could possibly result in judgments, settlements or administrative or judicial decrees requiring re-labeling or restriction on the manufacturing, sale, or distribution of products, or could require us to take other actions, including recalls, to pay fines or civil damages, or to be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations. Most of the STERIS SYSTEM 1 sales are within the United States. It is unclear what impact the FDA's action, litigation, or other events described may have on sales of the device outside the United States. We intend to continue our discussions with the FDA to seek resolution of all issues described in the warning letter, the December 3rd notice and any related proceedings or investigation.

For additional information regarding this matter, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2009 filed with the SEC on May 29, 2009: "Business Information with respect to our Business in General," "Recent Events," "Government Regulations," "Risk Factors." We are subject to extensive regulatory requirements and must receive and maintain regulatory clearance or approval for many products and operations. Failure to receive or maintain, or delays in receiving, clearance or approvals may hurt our revenues, profitability, financial condition or value. "Risk Factors." We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters. "Risk Factors." Most of our products, including our new liquid chemical sterilant system, must receive regulatory approvals before they can be marketed and sold in the United States and other countries. "Risk Factors." Existing and new Customers may not purchase or use the new liquid chemical sterilant system consistent with the purchase and use of existing STERIS SYSTEM 1[®], and see Item 1A. below.

From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.

Except as noted above, we believe there have been no material recent developments concerning our legal proceedings since September 30, 2009 and no new material pending legal proceedings that are required to be reported.

ITEM 1A. RISK FACTORS

The following supplements the risk factors that were included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2009, filed with the SEC on May 29, 2009:

Our business may be adversely affected as a result of the December 3, 2009 U.S. Food and Drug Administration notice to healthcare administrators.

Table of Contents

FDA's December 3, 2009 notice advises healthcare administrators that the FDA believes we have significantly modified STERIS SYSTEM 1, and therefore, were required to submit a new premarket notification to the FDA. As a result, the agency stated that it has not determined that STERIS SYSTEM 1 is safe or effective for sterilizing medical devices. The FDA recommends in the notice that Customers transition to an acceptable alternative as soon as possible if they have one; if not, that they promptly assess their patient care needs and sterilization and disinfection requirements and take steps to obtain legally-marketed STERIS SYSTEM 1 substitutes. As a result of this notice, some Customers may quickly transition away from or terminate the use of STERIS SYSTEM 1, reduce or discontinue the purchase of sterilant and services relating to STERIS SYSTEM 1, reduce or discontinue purchases of other STERIS products, including other STERIS products that the FDA considers acceptable alternatives, or take other action that could materially adversely affect our business. These Customers also may be disinclined to purchase our new liquid chemical sterilant system, now pending before the FDA, and there is no assurance that the FDA will clear the device. We may offer incentives and/or other consideration to Customers in conjunction with this situation. Revenues lost, transition costs incurred, incentives or other consideration provided, claims and compliance costs, and other expenses incurred and impact resulting from these circumstances, may have a material adverse effect on our business, performance, prospects, value, financial condition and results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the third quarter of fiscal 2010, we did not repurchase any of our common shares under our repurchase program. A repurchase program was approved by the Company's Board of Directors and announced on March 14, 2008, which authorized the repurchase of up to \$300.0 million of our common shares. As of December 31, 2009, \$203.9 million in common shares remained available for repurchase under this authorization. This common share repurchase authorization does not have a stated maturity date. The following table summarizes the common shares repurchased during the third quarter of fiscal 2010 under our common share repurchase program:

	(a) Total Number of Shares Purchased	(b) Average Price Paid Per Share	(c) Total Number of Shares Purchased as Part of Publicly Announced Plans	(d) Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans at Period End
October 1-31		\$		\$ 203,864
November 1-30				203,864
December 1-31				203,864
Total	(*)	\$ (*)		\$ 203,864

(*) Does not include 654 common shares obtained by the Company in payment of the required income tax withholdings related to the vesting of a Company restricted stock award.

ITEM 5. OTHER INFORMATION

On February 8, 2010, our Board of Directors approved a form of indemnification agreement for directors and executive officers. The indemnification agreement supplements and clarifies the indemnification rights provided by the Company's Amended and Restated Code of Regulations. The indemnification agreement provides, among other things, that the Company will indemnify its directors and applicable executive officers to the fullest extent permitted by Ohio law, including the advancement of legal fees and other expenses incurred by the directors and/or executive officers in connection with any threatened, pending or completed action, suit, demand or proceeding, whether of a civil, criminal, administrative, arbitrative or investigative nature, arising out of the individual's service as a director or executive officer of the Company or to any other entity to which he or she provides services at the Company's request, subject to certain exclusions and procedures set forth in the indemnification agreement.

Table of Contents

ITEM 6. EXHIBITS

Exhibits required by Item 601 of Regulation S-K

Exhibit

Number	Exhibit Description
3.1	1992 Amended Articles of Incorporation of STERIS Corporation, as amended on May 14, 1996, November 6, 1996, and August 6, 1998 (filed as Exhibit 3.1 to Form 10-K filed for the fiscal year ended March 31, 2000 (Commission File No. 1-14643), and incorporated herein by reference).
3.2	Amended and Restated Regulations of STERIS Corporation, as amended on July 26, 2007 (filed as Exhibit 3.2 to Form 10-Q for the fiscal quarter ended June 30, 2007 (Commission File No. 1-14643), and incorporated herein by reference).
4.1	Specimen Form of Common Stock Certificate (filed as Exhibit 4.1 to Form 10-K filed for the fiscal year ended March 31, 2002 (Commission File No. 1-14643), and incorporated herein by reference).
15.1	Letter Re: Unaudited Interim Financial Information.
31.1	Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

STERIS Corporation

/s/ MICHAEL J. TOKICH

Michael J. Tokich

Senior Vice President and Chief Financial Officer

February 9, 2010

Table of Contents

EXHIBIT INDEX

Exhibit

Number	Exhibit Description
3.1	1992 Amended Articles of Incorporation of STERIS Corporation, as amended on May 14, 1996, November 6, 1996, and August 6, 1998 (filed as Exhibit 3.1 to Form 10-K filed for the fiscal year ended March 31, 2000 (Commission File No. 1-14643), and incorporated herein by reference).
3.2	Amended and Restated Regulations of STERIS Corporation, as amended on July 26, 2007 (filed as Exhibit 3.2 to Form 10-Q for the fiscal quarter ended June 30, 2007 (Commission File No. 1-14643), and incorporated herein by reference).
4.1	Specimen Form of Common Stock Certificate (filed as Exhibit 4.1 to Form 10-K filed for the fiscal year ended March 31, 2002 (Commission File No. 1-14643), and incorporated herein by reference).
15.1	Letter Re: Unaudited Interim Financial Information.
31.1	Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant Section 906 of the Sarbanes-Oxley Act of 2002.